Practitioner’s Manual

An Informational Outline of the Controlled Substances Act

2006 Edition
Drug Enforcement Administration
Practitioner’s Manual

Joseph T. Rannazzisi
Deputy Assistant Administrator
Office of Diversion Control

Mark W. Caverly
Chief, Liaison and Policy Section

This manual has been prepared by the Drug Enforcement Administration, Office of Diversion Control, to assist practitioners (physicians, dentists, veterinarians, and other registrants authorized to prescribe, dispense, and administer controlled substances) in their understanding of the Federal Controlled Substances Act and its implementing regulations as they pertain to the practitioner’s profession.
# Table of Contents

**Section I - Introduction**

- Disclaimer: 1
- Authorization for Public Dissemination: 2
- Message from the Administrator: 3
- Preface: 4

**Section II – General Requirements**

- Schedules of Controlled Substances: 5
  - Schedule I Substances: 5
  - Schedule II Substances: 5
  - Schedule III Substances: 6
  - Schedule IV Substances: 6
  - Schedule V Substances: 6
- Registration Requirements: 7
  - Application for Registration: 7
  - Certificate of Registration: 8
  - Registration Renewals: 9
- Change of Business Address: 11
- Termination of Registration: 11
- Denial, Suspension or Revocation of Registration: 11
- Practitioner’s Use of a Hospital’s DEA Registration Number: 12
- Inappropriate Use of the DEA Registration Number: 12
- Exemption of Federal Government Practitioners from Registration: 13

**Section III – Security Requirements**

- Required Controls: 14
- Safeguards for Prescribers: 15

**Section IV – Recordkeeping Requirements**

- Recordkeeping Requirements: 16
  - Inventory: 16
  - Disposal of Controlled Substances: 17
Table of Contents (continued)

Section V – Valid Prescription Requirements

Prescription Requirements................................................................. 18
   Who May Issue............................................................................ 18
   Purpose of Issue......................................................................... 19
Schedule II Substances...................................................................... 19
   Refills....................................................................................... 19
   Issuance of Multiple Prescriptions for Schedule II Substances...... 19
   Facsimile Prescriptions for Schedule II Substances.................... 20
   Exceptions for Schedule II Facsimile Prescriptions..................... 21
Schedule III-V Substances............................................................... 21
   Refills....................................................................................... 21
   Facsimile Prescriptions for Schedule III-V Substances................. 22
   Telephone Authorization for Schedule III-V Prescriptions............. 22
Delivery of a Controlled Substance to Persons Outside the U.S............. 22

Section VI – Opioid (Narcotic) Addiction Treatment Programs

Opioid (Narcotic) Addiction Treatment Programs................................. 23

Appendices

Appendix A CSA and CFR Definitions.................................................. 26
Appendix B Questions and Answers.................................................... 28
Appendix C Summary of Controlled Substances Act Requirements........ 32
Appendix D Internet Resources.......................................................... 33
Appendix E DEA Diversion Field Office Locations............................... 34
Appendix F Small Business and Agriculture Regulatory Enforcement
   Ombudsman............................................................................... 40
Appendix G Additional Assistance and Plain Language Statements......... 41
Appendix H DEA Forms...................................................................... 42
   DEA Form 41 - Registrants Inventory of Drugs Surrendered............ 43
   DEA Form 106 – Report of Theft or Loss of Controlled Substances... 45
   DEA Form 222 - U.S. Official Order Form for Controlled Substances 47
   DEA Form 224 – Application for Registration............................... 48
   DEA Form 224a - Renewal Application for Registration............... 52
   DEA Form 363 - Application for Registration Under the Narcotic
      Addict Treatment Act of 1974................................................. 56
   DEA Form 363a – Renewal for Registration Under the Narcotic
      Addict Treatment Act of 1974................................................. 60
SECTION I - INTRODUCTION

This practitioner’s manual is intended to summarize and explain the basic requirements for prescribing, administering, and dispensing controlled substances under the Controlled Substances Act (CSA), 21 USC 801-890, and the DEA regulations, Title 21, Code of Federal Regulations (CFR), Parts 1300 to 1316. Pertinent citations to the law and regulations are included in this manual.

Printed copies of the CFR and the complete regulations implementing the CSA may be obtained from:

Superintendent of Documents
U.S. Government Printing Office
Washington, D.C. 20402

Both the CFR and the Federal Register (which includes proposed and final regulations implementing the CSA) are available on the Internet through the U.S. Government Printing Office (GPO) website. This website, which provides information by section, citation and keywords, can be accessed at:

www.gpoaccess.gov/cfr/index.html

Unofficial copies of pertinent CFR citations may be found at:

www.DEAdiversion.usdoj.gov

This practitioner’s manual may also be found on the Internet at DEA’s Web Site (under “publications”):

www.DEAdiversion.usdoj.gov

Should any pertinent provisions of the law or regulations be modified in the future, DEA will issue a revised electronic version of this document, which will be published on the DEA Diversion Website.

If you encounter errors in this document, please notify:

Editor, DEA Practitioner’s Manual
c/o DEA, Office of Diversion Control
Liaison and Policy Section
Washington, D.C. 20537

Inquiries regarding topics within this document may be addressed to your local DEA field office (listed in Appendix E) or the address above.

2006 Edition
Page 1
Drug Enforcement Administration
Practitioner’s Manual

------------------------------------------------------------------------------------------------------------

This Document is Authorized for Public Dissemination

All material in this publication is in the public domain and may be reproduced without the express permission of the Drug Enforcement Administration.
Message from the Administrator

The Drug Enforcement Administration is pleased to provide this updated edition of the 1990 Practitioner’s Manual to assist you in understanding your responsibilities under the Controlled Substances Act (CSA) and its implementing regulations. This manual will help answer questions that you may encounter in your practice and provide guidance in complying with federal requirements.

DEA remains committed to the 2001 Balanced Policy of promoting pain relief and preventing abuse of pain medications. In enforcing the CSA, it is DEA’s responsibility to ensure drugs are not diverted for illicit purposes. Unfortunately, this country is now experiencing an alarming prescription drug abuse problem:

- Today, more than 6 million Americans are abusing prescription drugs—that is more than the number of Americans abusing cocaine, heroin, hallucinogens, and inhalants, combined.

- Researchers from the Centers for Disease Control and Prevention report that opioid prescription painkillers now cause more drug overdose deaths than cocaine and heroin combined.

- Today more new drug users have begun abusing pain relievers (2.4 million) than marijuana (2.1 million) or cocaine (1.0 million).

It is more important now than ever to be vigilant in preventing the diversion and abuse of controlled substances. This manual will help you do that by listing some safeguards you can take to prevent such diversion. It also explains registration, recordkeeping, and valid prescription requirements.

As a practitioner, your role in the proper prescribing, administering, and dispensing of controlled substances is critical to patients’ health and to safeguarding society against the diversion of controlled substances. DEA is committed to working jointly with the medical community to ensure that those in need are cared for and that legitimate controlled substances are not being diverted for illegal use.

Karen P. Tandy
Administrator
September 2006
Preface

The Drug Enforcement Administration (DEA) was established in 1973 to serve as the primary federal agency responsible for the enforcement of the Controlled Substances Act (CSA). The CSA sets forth the federal law regarding both illicit and licit (pharmaceutical) controlled substances. With respect to pharmaceutical controlled substances, DEA’s statutory responsibility is twofold: to prevent diversion and abuse of these drugs while ensuring an adequate and uninterrupted supply is available to meet the country’s legitimate medical, scientific, and research needs. In carrying out this mission, DEA works in close cooperation with state and local authorities and other federal agencies.

Under the framework of the CSA, the DEA is responsible for ensuring that all controlled substance transactions take place within the “closed system” of distribution established by Congress. Under this “closed system,” all legitimate handlers of controlled substances – manufacturers, distributors, physicians, pharmacies, and researchers – must be registered with DEA and maintain strict accounting for all distributions.

To carry out DEA’s mission effectively, this 2006 Practitioner’s Manual seeks to aid DEA registrants in complying with the CSA and its implementing regulations. The DEA understands that it can best serve the public interest by working with practitioners to prevent diversion of legal pharmaceutical controlled substances into the illicit market.

The federal controlled substances laws are designed to work in tandem with state controlled substance laws. Toward this same goal, DEA works in close cooperation with state professional licensing boards and state and local law enforcement officials to ensure that pharmaceutical controlled substances are prescribed, administered, and dispensed for legitimate medical purposes in accordance with federal and state laws. Within this cooperative framework, the majority of investigations into possible violations of the controlled substances laws are carried out by state authorities. However, DEA also conducts investigations into possible violations of federal law as circumstances warrant.

In the event a state board revokes the license of a practitioner, the DEA will take action and request a voluntary surrender of the practitioner’s DEA registration. If the practitioner refuses to voluntarily surrender the registration, the DEA will pursue administrative action to revoke the DEA registration. The DEA may also pursue judicial action if there is sufficient evidence of illegal distribution or significant recordkeeping violations. All such actions are intended to deny the practitioner the means to continue to divert or abuse controlled substances as well as to protect the health and safety of the public and the practitioner.

The DEA is authorized under federal law to pursue legal action in order to prevent the diversion of controlled substances and protect the public safety. A lack of compliance may result in a need for corrective action, such as administrative action (that is, Letter of Admonition, an informal hearing or “order to show cause”), or in extreme cases, civil, or criminal action.
SECTION II – GENERAL REQUIREMENTS

Schedules of Controlled Substances

The drugs and other substances that are considered controlled substances under the CSA are divided into five schedules. A complete list of the schedules is published annually on an updated basis in the DEA regulations, Title 21 of the Code of Federal Regulations, Sections 1308.11 through 1308.15. Substances are placed in their respective schedules based on whether they have a currently accepted medical use in treatment in the United States and their relative abuse potential and likelihood of causing dependence when abused. Some examples of the drugs in each schedule are outlined below.

IMPORTANT NOTE:

All drugs listed in Schedule I have no currently accepted medical use in treatment in the United States and therefore may not be prescribed, administered, or dispensed for medical use. In contrast, drugs listed in Schedules II through V all have some accepted medical use and therefore may be prescribed, administered, or dispensed for medical use.

Schedule I Substances

Substances in this schedule have no currently accepted medical use in treatment in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.

Some examples of substances listed in Schedule I are: heroin; lysergic acid diethylamide (LSD); marijuana (cannabis); peyote; methaqualone; and methylene-dimethoxy-methamphetamine (“ecstasy”).

The CSA allows for bona fide research with controlled substances in Schedule I, provided that the FDA has determined the researcher to be qualified and competent, and provided further that the FDA has determined the research protocol to be meritorious. Researchers who meet these criteria must obtain a separate registration to conduct research with a Schedule I controlled substance.

Schedule II Substances

Substances in this schedule have a high potential for abuse with severe psychological or physical dependence.

Examples of single entity Schedule II narcotics include morphine, codeine, and opium. Other Schedule II narcotic substances and their common name brand products include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®), and fentanyl (Sublimaze® or Duragesic®).
Examples of Schedule II stimulants include amphetamine (Dexedrine® or Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®). Other Schedule II substances include: cocaine, amobarbital, glutethimide, and pentobarbital.

**Schedule III Substances**

Substances in this schedule have a potential for abuse less than substances in Schedules I or II.

Examples of Schedule III narcotics include combination products containing less than 15 milligrams of hydrocodone per dosage unit (i.e., Vicodin®) and products containing not more than 90 milligrams of codeine per dosage unit (i.e., Tylenol with codeine®).

Examples of Schedule III non-narcotics include benzphetamine (Didrex®), phendimetrazine, dronabinol (Marinol®), ketamine, and anabolic steroids such as oxandrolone (Oxandrin®).

**Schedule IV Substances**

Substances in this schedule have a lower potential for abuse relative to substances in Schedule III.

Examples of a Schedule IV narcotics include propoxyphene (Darvon® and Darvocet-N 100®).

Other Schedule IV substances include alprazolam (Xanax®), clonazepam (Klonopin®), clorazepate (Tranxene®), diazepam (Valium®), lorazepam (Ativan®), midazolam (Versed®), temazepam (Restoril®), and triazolam (Halcion®).

**Schedule V Substances**

Substances in this schedule have a lower potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotic and stimulant drugs. These are generally used for antitussive, ant diarrheal and analgesic purposes.

Examples include cough preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams (Robitussin AC®, and Phenergan with Codeine®).
Registration Requirements

Under the CSA, the term “practitioner” is defined as a physician, dentist, veterinarian, scientific investigator, pharmacy, hospital, or other person licensed, registered, or otherwise permitted, by the United States or the jurisdiction in which the practitioner practices or performs research, to distribute, dispense, conduct research with respect to, administer, or use in teaching or chemical analysis, a controlled substance in the course of professional practice or research. Every person or entity that handles controlled substances must be registered with DEA or be exempt by regulation from registration.

The DEA registration grants practitioners federal authority to handle controlled substances. However, the DEA registered practitioner may only engage in those activities that are authorized under state law for the jurisdiction in which the practice is located. When federal law or regulations differ from state law or regulations, the practitioner is required to abide by the more stringent aspects of both the federal and state requirements. In many cases, state law is more stringent than federal law, and must be complied with in addition to federal law. Practitioners should be certain they understand their state as well as DEA controlled substance regulations.

Application for Registration

To obtain a DEA registration, a practitioner must apply using a DEA Form 224. Applicants may submit the form by hard copy or on-line. Complete instructions accompany the form. To obtain the application, DEA may be contacted at:

- www.DEAdiversion.usdoj.gov (DEA Diversion Internet Web Site)
- any DEA field office (see listing in Appendix E of this manual)
- DEA Headquarters’ Registration Section in Washington, D.C. at 1-800-882-9539 (Registration Call Center)

The DEA Form-224 may be completed on-line or in hard copy and mailed to:

Drug Enforcement Administration
Attn: ODR
P.O. Box 2639
Springfield, VA 22152-263

A sample DEA Form 224 – New Application for Registration, is located at Appendix H, DEA Forms.
Certificate of Registration

The DEA Certificate of Registration (DEA Form 223) must be maintained at the registered location in a readily retrievable manner and kept available for official inspection.

The CSA requires that a separate registration be obtained for each principal place of business or professional practice where controlled substances are manufactured, distributed, or dispensed. DEA has historically provided an exception that a practitioner who is registered at one location, but also practices at other locations, is not required to register separately for any other location at which controlled substances are only prescribed. If the practitioner maintains supplies of controlled substances, administers, or directly dispenses controlled substances at the separate location the practitioner must obtain a separate DEA registration for that location. The exception applies only to a secondary location within the same state in which the practitioner maintains his/her registration. DEA individual practitioner registrations are based on state authority to dispense or conduct research with respect to controlled substances. Since a DEA registration is based on a state license, it cannot authorize controlled substance dispensing outside that state. Hence, the separate registration exception applies only to locations within the same state in which practitioners have their DEA registrations.
A duplicate Certificate of Registration may be requested on-line. It appears on DEA’s website, www.DEAdiversion.usdoj.gov, as follows:

**DEA Form 223 Duplicate Certificate Login:**

- **DEA Number (Required - Not Case Sensitive)**
- **Last Name or Business Name (Required - Not Case Sensitive)**
  - As it appears on your registration: Example
  - If "Smith, John Q MD" is on your registration, then enter: Smith
  - If "Smith's, Pharmacy" is on your registration, then enter: Smith's
  - If "Smith's Pharmacy" (no comma) is on your registration, then enter: Smith's Pharmacy
- **SSN (Required if given on application)**
- **Tax ID (Required if given on application)**

**Note:** If you renewed your registration recently, your duplicate certificate may not contain the new expire date, as some processing time is required.

### Registration Renewals

Practitioner registrations must be renewed every three years. Renewal registrations use DEA Form 224a, Renewal Application for DEA Registration (see example at Appendix H, DEA Forms). The cost of the registration is indicated on the application form.

A renewal application is sent to the registrant approximately 45 days before the registration expiration date. The renewal application is sent to the address listed on the current registration certificate. If the renewal form is not received within 30 days before the expiration date of the current registration, the practitioner should contact the DEA registration office for their state, or DEA Headquarters at 1-800-882-9539, and request a renewal registration form.
The registration renewal application may be completed on-line at www.DEAdversion.usdoj.gov, or in hard copy and mailed to:

Drug Enforcement Administration
Attn: ODR
P.O. Box 2639
Springfield, VA 22152-2639

Registration Applications

Office of Diversion Control Web Interactive Forms (ODWIF)

RENEWAL APPLICATIONS

<table>
<thead>
<tr>
<th>Login to Begin Renewal Process</th>
<th>Retail Pharmacy, Hospital/Clinic, Practitioner, Teaching Institution, or Mid-Level Practitioner, Manufacturer, Distributor, Researcher, Analytical Laboratory, Importer, Exporter, Domestic Chemicals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obtain Receipt</td>
<td>This link may be used ONLY if you have previously submitted a Renewal Application through this tool and need an additional receipt.</td>
</tr>
<tr>
<td>Duplicate Certificate</td>
<td>On-line tool to request certificates for additional, misplaced, illegible, or destroyed originals.</td>
</tr>
</tbody>
</table>

MINIMUM ON-LINE REQUIREMENTS

The DEA Forms listed below are for those applying to DEA for a controlled substance registration. Data will be entered through a secure connection to the ODWIF on-line web application system. Your web browser must support 128-bit encryption.

You will need to have the following information handy in order to complete the form:

- Tax ID number and/or Social Security Number
- State Controlled Substance Registration Information
- State Medical License Information
- Credit Card (VISA, MasterCard, Discover or American Express)

The ODWIF system can only process credit card transactions at this time. If you are paying by check, you will need to use the PDF version of the form, then print and mail the form to the address listed on the form.
Change of Business Address

A practitioner who moves to a new physical location must request a modification of registration. A modification of registration can be requested online at www.DEAdiversion.usdoj.gov or in writing to the DEA field office responsible for that state. If the change in address involves a change in state, the proper state issued license and controlled substances registration must be obtained prior to the approval of modification of the federal registration. If the modification is approved, DEA will issue a new certificate of registration and, if requested, new Schedule II order forms (DEA Form-222, Official Order Form). A Renewal Application for Registration (DEA Form-224a) will only be sent to the registered address on file with DEA. It will not be forwarded.

Termination of Registration

Any practitioner desiring to discontinue business activities with respect to controlled substances must notify the nearest DEA field office (see Appendix E) in writing. Along with the notification of termination of registration, the practitioner should send the DEA Certificate of Registration and any unused Official Order Forms (DEA Form-222) to the nearest DEA field office.

Denial, Suspension or Revocation of Registration

Under the CSA, DEA has the authority to deny, suspend, or revoke a DEA registration upon a finding that the registrant has:

1. Materially falsified any application filed
2. Been convicted of a felony relating to a controlled substance or a List I chemical
3. Had their state license or registration suspended, revoked, or denied
4. Committed an act which would render the DEA registration inconsistent with the public interest
5. Been excluded from participation in a Medicaid or Medicare program

In determining the public interest, the CSA states the following factors are to be considered:

1. The recommendation of the appropriate state licensing board or professional disciplinary authority
2. The applicant’s experience in dispensing or conducting research with respect to controlled substances
3. The applicant’s conviction record under federal or state laws relating to the manufacture, distribution, or dispensing of controlled substances
4. Compliance with applicable state, federal, or local laws relating to controlled substances
5. Such other conduct which may threaten the public health and safety
Practitioner’s Use of a Hospital’s DEA Registration Number

Practitioners (e.g., intern, resident, staff physician, mid-level practitioner) who are agents or employees of a hospital or other institution may, when acting in the usual course of business or employment, administer, dispense, or prescribe controlled substances under the registration of the hospital or other institution in which they are employed, provided that:

1. The dispensing, administering, or prescribing is in the usual course of professional practice
2. Practitioners are authorized to do so by the state in which they practice
3. The hospital or institution has verified that the practitioner is permitted to dispense, administer or prescribe controlled substances within the state
4. The practitioner acts only within the scope of employment in the hospital or institution
5. The hospital or institution authorizes the practitioner to dispense or prescribe under its registration and assigns a specific internal code number for each practitioner so authorized (See example of a specific internal code number below):

| Hospital DEA Registration Number | AB1234567-012 | Physician’s Hospital Code Number |

A current list of internal codes and the corresponding individual practitioners is to be maintained by the hospital or other institution. This list is to be made available at all times to other registrants and law enforcement agencies upon request for the purpose of verifying the authority of the prescribing individual practitioner.

Inappropriate Use of the DEA Registration Number

DEA strongly opposes the use of a DEA registration number for any purpose other than the one for which it was intended, to provide certification of DEA registration in transactions involving controlled substances. The use of DEA registration numbers as an identification number is not an appropriate use and could lead to a weakening of the registration system.

The Centers for Medicare and Medicaid Services has developed a National Provider Identification (NPI) number unique to each healthcare provider. The Final Rule for establishment of the NPI system was published in the Federal Register (FR 3434, Vol. 69, No. 15) by the Department of Health and Human Services on January 23, 2004. The effective date of this Final Rule was May 23, 2005; all covered entities must begin using the NPI in standard transactions by May 23, 2007.
Exemption of Federal Government Practitioners from Registration

The requirement of registration is waived for any official of the U.S. Army, Navy, Marine Corps, Air Force, Coast Guard, Public Health Service, or Bureau of Prisons who is authorized to prescribe, dispense, or administer, but not to procure or purchase controlled substances in the course of his/her official duties. Such officials shall follow procedures set forth in Title 21, CFR § 1306 regarding prescriptions, but shall state the branch of service or agency (e.g., "U.S. Army" or "Public Health Service") and the service identification number of the issuing official in lieu of the registration number required on prescription forms. The service identification number for a Public Health Service employee is his/her Social Security identification number.

If Federal Government practitioners wish to maintain a DEA registration for a private practice, which would include prescribing for private patients, they must be fully licensed to handle controlled substances by the state in which they are located. Under these circumstances, the Federal Government practitioner will not be eligible for the fee exemption and must pay a fee for the registration.
SECTION III – SECURITY REQUIREMENTS

Required Controls

Title 21, CFR Section 1301.71(a), requires that all registrants provide effective controls and procedures to guard against theft and diversion of controlled substances. A list of factors is used to determine the adequacy of these security controls. Factors affecting practitioners include:

1. The location of the premises and the relationship such location bears on security needs
2. The type of building and office construction
3. The type and quantity of controlled substances stored on the premises
4. The type of storage medium (safe, vault, or steel cabinet)
5. The control of public access to the facility
6. The adequacy of registrant’s monitoring system (alarms and detection systems)
7. The availability of local police protection

Practitioners are required to store stocks of Schedule II through V controlled substances in a securely locked, substantially constructed cabinet. Practitioners authorized to possess carfentanil, etorphine hydrochloride and/or diprenorphine, must store these controlled substances in a safe or steel cabinet equivalent to a U.S. Government Class V security container.

Registrants should not employ as an agent or employee who has access to controlled substances:

1. Any person who has been convicted of a felony offense related to controlled substances
2. Any person who has been denied a DEA registration
3. Any person who has had a DEA registration revoked
4. Any person who has surrendered a DEA registration for cause

Lastly, practitioners should notify the DEA, upon discovery, of any thefts or significant losses of controlled substances and complete a DEA Form 106 regarding such theft or loss.
Safeguards for Prescribers

In addition to the required security controls, practitioners can utilize additional measures to ensure security. These include:

1. Keep all prescription blanks in a safe place where they cannot be stolen; minimize the number of prescription pads in use.

2. Write out the actual amount prescribed in addition to giving a number to discourage alterations of the prescription order.

3. Use prescription blanks only for writing a prescription order and not for notes.


5. Assist the pharmacist when they telephone to verify information about a prescription order; a corresponding responsibility rests with the pharmacist who dispenses the prescription order to ensure the accuracy of the prescription.

6. Contact the nearest DEA field office (see Appendix E) to obtain or to furnish information regarding suspicious prescription activities.

7. Use tamper-resistant prescription pads.
SECTION IV – RECORDKEEPING REQUIREMENTS

Recordkeeping Requirements

Each practitioner must maintain inventories and records of controlled substances listed in Schedules I and II separately from all other records maintained by the registrant. Likewise, inventories and records of controlled substances in Schedules III, IV, and V must be maintained separately or in such a form that they are readily retrievable from the ordinary business records of the practitioner. All records related to controlled substances must be maintained and be available for inspection for a minimum of two years.

A registered practitioner is required to keep records of controlled substances that are dispensed to the patient, other than by prescribing or administering, in the lawful course of professional practice. A registered practitioner is not required to keep records of controlled substances that are prescribed in the lawful course of professional practice, unless such substances are prescribed in the course of maintenance or detoxification treatment. A registered practitioner is not required to keep records of controlled substances that are administered in the lawful course of professional practice unless the practitioner regularly engages in the dispensing or administering of controlled substances and charges patients, either separately or together with charges for other professional services, for substances so dispensed or administered. A registered practitioner is also required to keep records of controlled substances administered in the course of maintenance or detoxification treatment of an individual.

Inventory

Each registrant who maintains an inventory of controlled substances must maintain a complete and accurate record of the controlled substances on hand and the date that the inventory was conducted. This record must be in written, typewritten, or printed form and be maintained at the registered location for at least two years from the date that the inventory was conducted. After an initial inventory is taken, the registrant shall take a new inventory of all controlled substances on hand at least every two years.

Each inventory must contain the following information:

1. Whether the inventory was taken at the beginning or close of business
2. Names of controlled substances
3. Each finished form of the substances (e.g., 100 milligram tablet)
4. The number of dosage units of each finished form in the commercial container (e.g., 100 tablet bottle)
5. The number of commercial containers of each finished form (e.g., four 100 tablet bottles)
6. Disposition of the controlled substances

It is important to note that inventory requirements extend to controlled substance samples provided to practitioners by pharmaceutical companies.

Disposal of Controlled Substances

A practitioner may dispose of out-of-date, damaged, or otherwise unusable or unwanted controlled substances, including samples, by transferring them to a registrant who is authorized to receive such materials. These registrants are referred to as “Reverse Distributors.” The practitioner should contact the local DEA field office (See Appendix E) for a list of authorized Reverse Distributors. Schedule I and II controlled substances should be transferred via the DEA Form 222, while Schedule III–V compounds may be transferred via invoice. The practitioner should maintain copies of the records documenting the transfer and disposal of controlled substances for a period of two years.
SECTION V – VALID PRESCRIPTION REQUIREMENTS

Prescription Requirements

A prescription is an order for medication which is dispensed to or for an ultimate user. A prescription is not an order for medication which is dispensed for immediate administration to the ultimate user (for example, an order to dispense a drug to an inpatient for immediate administration in a hospital is not a prescription).

A prescription for a controlled substance must be dated and signed on the date when issued. The prescription must include the patient’s full name and address, and the practitioner’s full name, address, and DEA registration number. The prescription must also include:

1. drug name
2. strength
3. dosage form
4. quantity prescribed
5. directions for use
6. number of refills (if any) authorized

A prescription for a controlled substance must be written in ink or indelible pencil or typewritten and must be manually signed by the practitioner on the date when issued. An individual (secretary or nurse) may be designated by the practitioner to prepare prescriptions for the practitioner’s signature.

The practitioner is responsible for ensuring that the prescription conforms to all requirements of the law and regulations, both federal and state.

Who May Issue

A prescription for a controlled substance may only be issued by a physician, dentist, podiatrist, veterinarian, mid-level practitioner, or other registered practitioner who is:

1. Authorized to prescribe controlled substances by the jurisdiction in which the practitioner is licensed to practice
2. Registered with DEA or exempted from registration (that is, Public Health Service, Federal Bureau of Prisons, or military practitioners)
3. An agent or employee of a hospital or other institution acting in the normal course of business or employment under the registration of the hospital or other institution which is registered in lieu of the individual practitioner being registered provided that additional requirements as set forth in the CFR are met.
Purpose of Issue

To be valid, a prescription for a controlled substance must be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. The practitioner is responsible for the proper prescribing and dispensing of controlled substances. In addition, a corresponding responsibility rests with the pharmacist who fills the prescription. An order purporting to be a prescription issued not in the usual course of professional treatment or in legitimate and authorized research is not a valid prescription within the meaning and intent of the Controlled Substances Act and the person knowingly filling such a purported prescription, as well as the person issuing it, shall be subject to the penalties provided for violations of the provisions of law relating to controlled substances.

A prescription may not be issued in order for an individual practitioner to obtain controlled substances for supplying the individual practitioner for the purpose of general dispensing to patients.

Schedule II Substances

Schedule II controlled substances require a written prescription which must be signed by the practitioner. There is no federal time limit within which a Schedule II prescription must be filled after being signed by the practitioner.

While some states and many insurance carriers limit the quantity of controlled substance dispensed to a 30-day supply, there are no specific federal limits to quantities of drugs dispensed via a prescription. For Schedule II controlled substances, an oral order is only permitted in an emergency situation.

Refills

The refilling of a prescription for a controlled substance listed in Schedule II is prohibited (Title 21 U.S. Code § 829(a)).

Issuance of Multiple Prescriptions for Schedule II Substances

DEA has revised its regulations regarding the issuance of multiple prescriptions for schedule II controlled substances. Under the new regulation, which became effective December 19, 2007, an individual practitioner may issue multiple prescriptions authorizing the patient to receive a total of up to a 90-day supply of a schedule II controlled substance provided the following conditions are met:

1. Each separate prescription is issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice.
2. The individual practitioner provides written instructions on each prescription (other than the first prescription, if the prescribing practitioner intends for that prescription to be filled immediately) indicating the earliest date on which a pharmacy may fill each prescription.

3. The individual practitioner concludes that providing the patient with multiple prescriptions in this manner does not create an undue risk of diversion or abuse.

4. The issuance of multiple prescriptions is permissible under applicable state laws.

5. The individual practitioner complies fully with all other applicable requirements under the Controlled Substances Act and Code of Federal Regulations, as well as any additional requirements under state law.

It should be noted that the implementation of this change in the regulation should not be construed as encouraging individual practitioners to issue multiple prescriptions or to see their patients only once every 90 days when prescribing schedule II controlled substances. Rather, individual practitioners must determine on their own, based on sound medical judgment, and in accordance with established medical standards, whether it is appropriate to issue multiple prescriptions and how often to see their patients when doing so.

**Facsimile Prescriptions for Schedule II Controlled Substances**

In order to expedite the filling of a prescription, a prescriber may transmit a Schedule II prescription to the pharmacy by facsimile. The original Schedule II prescription must be presented to the pharmacist for review prior to the actual dispensing of the controlled substance.

In an emergency, a practitioner may call-in a prescription for a Schedule II controlled substance by telephone to the pharmacy, and the pharmacist may dispense the prescription provided that the quantity prescribed and dispensed is limited to the amount adequate to treat the patient during the emergency period. The prescribing practitioner must provide a written and signed prescription to the pharmacist within seven days. Further, the pharmacist must notify DEA if the prescription is not received.
Exceptions for Schedule II Facsimile Prescriptions

DEA has granted three exceptions to the facsimile prescription requirements for Schedule II controlled substances. The facsimile of a Schedule II prescription may serve as the original prescription as follows:

1. A practitioner prescribing Schedule II narcotic controlled substances to be compounded for the direct administration to a patient by parenteral, intravenous, intramuscular, subcutaneous or intraspinal infusion may transmit the prescription by facsimile. The pharmacy will consider the facsimile prescription a “written prescription” and no further prescription verification is required. All normal requirements of a legal prescription must be followed.

2. Practitioners prescribing Schedule II controlled substances for residents of Long Term Care Facilities (LTCF) may transmit a prescription by facsimile to the dispensing pharmacy. The practitioner’s agent may also transmit the prescription to the pharmacy. The facsimile prescription serves as the original written prescription for the pharmacy.

3. A practitioner prescribing a Schedule II narcotic controlled substance for a patient enrolled in a hospice care program certified and/or paid for by Medicare under Title XVIII or a hospice program which is licensed by the state may transmit a prescription to the dispensing pharmacy by facsimile. The practitioner or the practitioner’s agent may transmit the prescription to the pharmacy. The practitioner or agent will note on the prescription that it is for a hospice patient. The facsimile serves as the original written prescription.

Schedule III-V Substances

A prescription for controlled substances in Schedules III, IV, and V issued by a practitioner, may be communicated either orally, in writing, or by facsimile to the pharmacist, and may be refilled if so authorized on the prescription or by call-in.

Refills

Schedule III and IV controlled substances may be refilled if authorized on the prescription. However, the prescription may only be refilled up to five times within six months after the date on which the prescription was issued. After five refills or after six months, whichever occurs first, a new prescription is required.
Facsimile Prescriptions for Schedule III-V Substances

Prescriptions for Schedules III-V controlled substances may be transmitted by facsimile from the practitioner or an employee or agent of the individual practitioner to the dispensing pharmacy. The facsimile is considered to be equivalent to an original prescription.

Telephone Authorization for Schedule III-V Prescriptions

A pharmacist may dispense a controlled substance listed in Schedule III, IV, or V pursuant to an oral prescription made by an individual practitioner and promptly reduced to writing by the pharmacist containing all information required for a valid prescription, except for the signature of the practitioner.

Delivery of a Controlled Substance to Persons Outside the U.S.

Controlled substances that are dispensed pursuant to a legitimate prescription may not be delivered or shipped to individuals in another country. Any such delivery or shipment is a prohibited export under the CSA.
SECTION VI – OPIOID (NARCOTIC) ADDICTION TREATMENT PROGRAMS

The Narcotic Addiction Treatment Act of 1974 and the Drug Addiction Treatment Act of 2000 amended the CSA with respect to the use of controlled substances in the medical treatment of addiction. These laws established the procedures for approval and licensing of practitioners involved in the treatment of opioid addiction as well as improving the quality and delivery of that treatment to the segment of society in need.

Practitioners wishing to administer and dispense approved Schedule II controlled substances (that is, methadone) for maintenance and detoxification treatment must obtain a separate DEA registration as a Narcotic Treatment Program. Application for registration as a Narcotic Treatment Program is made using DEA Form 363. In addition to obtaining this separate DEA registration, this type of activity also requires the approval and registration of the Center for Substance Abuse Treatment (CSAT) within the Substance Abuse and Mental Health Services Administration (SAMHSA) of the Department of Health and Human Services (HHS), as well as the applicable state methadone authority.

If a practitioner wishes to prescribe, administer, or dispense Schedule III, IV, or V controlled substances approved for addiction treatment (i.e., buprenorphine drug products), the practitioner must request a waiver (Form SMA-167) and fulfill the requirements of CSAT. CSAT will then notify DEA of all waiver requests. DEA will review each request. If DEA approves this waiver, the practitioner will receive a Unique Identification Number. If a practitioner chooses to dispense controlled substances, the practitioner must maintain, separate from all other records, for a period of at least two years, all required records of receipt, storage, and distribution. If a practitioner chooses to prescribe these controlled substances, the practitioner must utilize their Unique Identification Number on the prescription in addition to his/her regular DEA registration number. The practitioner must also maintain a record of each such prescription for a period of at least two years. Practitioners should be aware that there may be limits on how many patients they may treat for opioid addiction at any given time and should check with SAMHSA to determine these limits.

Note that not all treatment programs utilize controlled substances, that is, some are drug free. Accordingly, these activities do not require DEA registration or approval.

Practitioners can find additional information regarding addiction treatment by visiting DEA’s Office of Diversion Control website at www.DEAdiversion.usdoj.gov. Click on “Publications,” then “Narcotic Treatment Programs: Best Practices Guidelines.” The DEA application Form 363 may be completed on-line.

To learn more about CSAT’s requirements, practitioners may visit one or more of the following websites: www.samhsa.gov/centers/csat2002/csat_frame.html, www.csat.samhsa.gov, or www.buprenorphine.samhsa.gov.
If the practitioner has a patient who is in need of addiction treatment, but does not wish to treat the individual, the practitioner can refer the patient to an existing facility through the following website: [www.findtreatment.samhsa.gov](http://www.findtreatment.samhsa.gov).
APPENDICES
APPENDIX A

CSA & CFR Definitions

Administer
The direct application of a controlled substance to the body of a patient or research subject by 1) a practitioner or (in his presence) by his authorized agent, or 2) the patient or research subject at the direction and in the presence of the practitioner, whether such application is by injection, inhalation, ingestion, or any other means.

Dispense
To deliver a controlled substance to an ultimate user or research subject by, or pursuant to the lawful order of, a practitioner, including the prescribing and administering of a controlled substance and the packaging, labeling, or compounding necessary to prepare the substance for such delivery.

Dispenser
An individual practitioner, institutional practitioner, pharmacy or, pharmacist who dispenses a controlled substance.

Individual Practitioner
A physician, dentist, veterinarian, or other individual licensed, registered or otherwise permitted, by the United States or the jurisdiction in which they practice, to dispense a controlled substance in the course of professional practice, but does not include a pharmacist, a pharmacy, or an institutional practitioner.

Institutional Practitioner
A hospital or other person (other than an individual) licensed, registered or otherwise permitted, by the United States or the jurisdiction in which it practices, to dispense a controlled substance in the course of professional practice, but does not include a pharmacy.

Inventory
All factory and branch stocks in finished form of a basic class of controlled substance manufactured or otherwise acquired by a registrant, whether in bulk, commercial containers, or contained in pharmaceutical preparations in the possession of the registrant (including stocks held by the registrant under separate registration as a manufacturer, importer, exporter, or distributor).
Long Term Care Facility
A nursing home, retirement care, mental care, or other facility or institution which provides extended health care to resident patients.

Mid-level Practitioner
An individual practitioner, other than a physician, dentist, veterinarian, or podiatrist, who is licensed, registered or otherwise permitted by the United States or the jurisdiction in which he/she practices, to dispense a controlled substance in the course of professional practice. Examples of mid-level practitioners include, but are not limited to, health care providers such as nurse practitioners, nurse midwives, nurse anesthetists, clinical nurse specialists, and physician assistants who are authorized to dispense controlled substances by the state in which they practice.

Pharmacist
Any pharmacist licensed by a state to dispense controlled substances, and shall include any other person (e.g., pharmacist intern) authorized by a state to dispense controlled substances under the supervision of a pharmacist licensed by such state.

Prescription
An order for medication which is dispensed to or for an ultimate user but does not include an order for medication which is dispensed for immediate administration to the ultimate user (e.g., an order to dispense a drug to a bed patient for immediate administration in a hospital is not a prescription).

Readily Retrievable
Certain records are kept by automatic data processing systems or other electronic or mechanized record keeping systems in such a manner that they can be separated out from all other records in a reasonable time and/or records are kept on which certain items are asterisked, redlined, or in some other manner visually identifiable apart from other items appearing on the records.
APPENDIX B

Questions and Answers

The following questions are those that are frequently encountered by DEA’s Office of Diversion Control and its field units. These questions and their accompanying answers are provided in context of the CSA and its federal regulations.

Q Are separate registrations required for separate locations?

A A separate registration is required for each principal place of business or professional practice where controlled substances are stored or dispensed by a person.

Q Does a practitioner need a separate registration to treat patients at remote health care facilities?

A Separate registration is not required in an office used by a practitioner (who is registered at another location) where controlled substances are prescribed but neither administered nor otherwise dispensed as a regular part of the professional practice of the practitioner at such office, and where no supplies of controlled substances are maintained.

Q Do all practitioners in a group practice need to be registered?

A An individual practitioner who is an agent or employee of another practitioner (other than a mid-level practitioner) registered to dispense controlled substances may, when acting in the normal course of business or employment, administer or dispense (other than by issuance of prescription) controlled substances if and to the extent that such individual practitioner is authorized or permitted to do so by the jurisdiction in which he or she practices, under the registration of the employer or principal practitioner in lieu of being registered him/herself.

Q Do medical residents assigned to hospitals need to register?

A An individual practitioner who is an agent or employee of a hospital or other institution may, when acting in the normal course of business or employment, administer, dispense, or prescribe controlled substances under the registration of the hospital or other institution which is registered in lieu of being registered provided that additional requirements as set forth in the CFR are met.
Q Are military personnel exempted from registration?

A Registration is waived for any official of the U.S. Army, Navy, Marine Corps, Air Force, or Coast Guard who is authorized to prescribe, dispense, or administer, but not procure or purchase, controlled substances in the course of his/her official duties. Such officials must follow procedures set forth in 21 CFR Part 1306 regarding prescriptions. Branch of service or agency and the service identification number of the issuing official is required on the prescription form in lieu of the DEA registration number.

If any exempted official engages as a private individual in any activity or group of activities for which registration is required, that individual must obtain a registration for those private activities.

Further, practitioners serving in the U.S. Military are exempt from registering with DEA, but are not authorized to procure or purchase controlled substances in the course of their official duties.

A number of states also require military practitioners to acquire a separate state license if they issue prescriptions that are filled outside the military facility where they practice.

Q Are contract practitioners working at U.S. Military Installations also exempt from registration?

A They are not exempt. A contract practitioner who is not an official of the military on active duty, but is engaged in medical practice at a military installation, must possess a current DEA registration. The individual must also possess a valid state license for the same state in which he/she is registered with DEA.

Q What should a practitioner do if he/she discovers a theft or loss?

A Registrants must notify the DEA field office in their area of the theft or significant loss of any controlled substances upon discovery. The registrant must also complete DEA Form 106 documenting the loss or theft.
Q What is meant by “acceptable medical practice?”

A The legal standard that a controlled substance may only be prescribed, administered, or dispensed for a legitimate medical purpose by a physician acting in the usual course of professional practice has been construed to mean that the prescription must be “in accordance with a standard of medical practice generally recognized and accepted in the United States.”

Federal courts have long recognized that it is not possible to expand on the phrase “legitimate medical purpose in the usual course of professional practice” in a way that will provide definitive guidelines to address all the varied situations physicians may encounter.

While there are no criteria to address every conceivable instance of prescribing, there are recurring patterns that may be indicative of inappropriate prescribing:

- An inordinately large quantity of controlled substances prescribed or large numbers of prescriptions issued compared to other physicians in an area;
- No physical examination was given;
- Warnings to the patient to fill prescriptions at different drug stores;
- Issuing prescriptions knowing that the patient was delivering the drugs to others;
- Issuing prescriptions in exchange for sexual favors or for money;
- Prescribing of controlled drugs at intervals inconsistent with legitimate medical treatment;
- The use of street slang rather than medical terminology for the drugs prescribed; or
- No logical relationship between the drugs prescribed and treatment of the condition allegedly existing.

Each case must be evaluated based on its own merits in view of the totality of circumstances particular to the physician and patient.

For example, what constitutes “an inordinately large quantity of controlled substances,” can vary greatly from patient to patient. A particular quantity of a powerful Schedule II opioid might be blatantly excessive for the treatment of a particular patient's mild temporary pain, yet insufficient to treat the severe unremitting pain of a cancer patient.

Q What information is required to be provided on a written prescription?

A All written prescriptions for controlled substances must be dated as of, and signed on, the date when issued. Each prescription must indicate the full name and address of the patient, the drug name, strength, dosage form, quantity prescribed,
directions for use and the name, address, and DEA number of the practitioner. Further, prescriptions must be written in ink, indelible pencil, or by typewriter, and must be manually signed by the practitioner.

Q **What is meant by “date of issuance?”**

A The date a prescription is issued is the same date that the prescribing practitioner actually writes and signs the prescription.

Q **Is there a time limit for filling Schedule II prescriptions?**

A There is no federal time limit for filling Schedule II prescriptions. However, some state laws do set time limits.
## APPENDIX C

### Summary of Controlled Substances Act Requirements

<table>
<thead>
<tr>
<th></th>
<th>Schedule II</th>
<th>Schedule III &amp; IV</th>
<th>Schedule V</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Registration</strong></td>
<td>Required</td>
<td>Required</td>
<td>Required</td>
</tr>
<tr>
<td><strong>Receiving Records</strong></td>
<td>Order Forms (DEA Form-222)</td>
<td>Invoices, Readily Retrievable</td>
<td>Invoices, Readily Retrievable</td>
</tr>
<tr>
<td><strong>Prescriptions</strong></td>
<td>Written Prescription (See exceptions*)</td>
<td>Written, Oral, or Fax</td>
<td>Written, Oral, Fax, or Over The Counter**</td>
</tr>
<tr>
<td><strong>Refills</strong></td>
<td>No</td>
<td>No more than 5 within 6 months</td>
<td>As authorized when prescription is issued</td>
</tr>
<tr>
<td><strong>Distribution Between Registrants</strong></td>
<td>Order Forms (DEA Form-222)</td>
<td>Invoices</td>
<td>Invoices</td>
</tr>
<tr>
<td><strong>Security</strong></td>
<td>Locked Cabinet or Other Secure Storage</td>
<td>Locked Cabinet or Other Secure Storage</td>
<td>Locked Cabinet or Other Secure Storage</td>
</tr>
<tr>
<td><strong>Theft or Significant Loss</strong></td>
<td>Report and complete DEA Form 106</td>
<td>Report and complete DEA Form 106</td>
<td>Report and complete DEA Form 106</td>
</tr>
</tbody>
</table>

Note: *All records* must be maintained for 2 years, unless a state requires a longer period.

* **Emergency prescriptions** require a signed follow-up prescription.
  
  *Exceptions:* A facsimile prescription serves as the original prescription when issued to residents of Long Term Care Facilities, Hospice patients, or compounded IV narcotic medications.

** Where authorized by state controlled substances authority.
APPENDIX D

Internet Resources

DEA’s Diversion Control Program Website
   www.DEAdversion.usdoj.gov

DEA Homepage
   www.dea.gov

U.S. Government Printing Office
   www.gpoaccess.gov/cfr/index.html

   Provides access to the Code of Federal Regulations (21 CFR, Parts 1300 to end),
   primary source for the Practitioner’s Manual, and the Federal Register which
   contains proposed and finalized amendments to the CFR.

Office of National Drug Control Policy (ONDCP)
   www.whitehousedrugpolicy.gov

Food and Drug Administration
   www.FDA.gov

HHS & SAMHSA’s National Clearinghouse for Alcohol and Drug
Information
   www.health.org

SAMHSA/CSAT
   www.csat.samhsa.gov

Federation of State Medical Boards
   www.FSMB.org

National Association of Boards of Pharmacy
   www.nabp.net

National Association of State Controlled Substances Authorities
   www.nascsa.org
Drug Enforcement Administration
Practitioner’s Manual

APPENDIX E

Drug Enforcement Administration
Diversion Field Office Locations

For address and telephone number updates, please see the DEA website:
https://www.deadiversion.usdoj.gov/contactDea/spring/fullSearch

Appendix E pages 34-39 of this manual contained outdated Field Office Information and therefore have been removed. Please refer to the above link for current Diversion Field Office Locations.
APPENDIX F

Small Business and Agriculture
Regulatory Enforcement Ombudsman

The Small Business and Agriculture Regulatory Enforcement Ombudsman and 10 Regional Fairness Boards were established to receive comments from small businesses about federal agency enforcement actions. The Ombudsman will annually evaluate the enforcement activities and rate each agency’s responsiveness to small business. If you wish to comment on DEA enforcement actions, you may contact the Ombudsman at 1-888-REG-FAIR (1-888-734-3247).
APPENDIX G

Additional Assistance

This publication is intended to provide guidance and information on the requirements of the Controlled Substances Act and its implementing regulations. If you require additional clarification or assistance, or wish to comment on any matter regarding the DEA’s requirements or regulatory activities, please contact your local DEA Diversion field office (see Appendix E). Every effort will be made to respond promptly to your inquiry.

Plain Language

The Drug Enforcement Administration has made every effort to write this manual in clear, plain language. If you have suggestions as to how to improve the clarity of this manual, please contact us at:

DEA Office of Diversion Control  
Attn: Liaison and Policy Section  
8701 Morrissette Drive  
Springfield, VA  20537  
Telephone: (202) 307-7297
APPENDIX H – DEA FORMS

The following pages provide samples of several forms frequently encountered by DEA registrants. Included are:

- **DEA Form 41** Registrants Inventory of Drugs Surrendered
- **DEA Form 106** Report of Theft or Loss of Controlled Substances
- **DEA Form 222** U.S. Official Order Form for Controlled Substances
- **DEA Form 224** Application for Registration
- **DEA Form 224a** Renewal Application for DEA Registration
- **DEA Form 363** Application for Registration as a Narcotic Treatment Program
- **DEA Form 363a** Renewal Application for DEA Registration as a Narcotic Treatment Program
REGISTRANTS INVENTORY OF DRUGS SURRENDERED

The following schedule is an inventory of controlled substances which is hereby surrendered to you for proper disposition.

FROM: (Include Name, Street, City, State and ZIP Code in space provided below.)

<table>
<thead>
<tr>
<th>Signature of applicant or authorized agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registrant's DEA Number</td>
</tr>
<tr>
<td>Registrant's Telephone Number</td>
</tr>
</tbody>
</table>

NOTE: CERTIFIED MAIL (Return Receipt Requested) IS REQUIRED FOR SHIPMENTS OF DRUGS VIA U.S. POSTAL SERVICE. See instructions on reverse page 2 of form.

<table>
<thead>
<tr>
<th>NAME OF DRUG OR PREPARATION</th>
<th>Number of Containers</th>
<th>CONTENTS (Number of grams, ounces, or other units per container)</th>
<th>Controlled Substance Constant (Each Unit)</th>
<th>FOR DEA USE ONLY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DISPOSITION</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>QUANTITY</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>GMS. MGS.</td>
</tr>
</tbody>
</table>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

FORM DEA-41 (8-41) Previous edition dated 6-86 is usable. See instructions on reverse (page 2) of form.
Drug Enforcement Administration
Practitioner’s Manual

<table>
<thead>
<tr>
<th>NAME OF DRUG OR PREPARATION</th>
<th>Number of Containers</th>
<th>CONTENTS (Number of grams, tablets, capsules, or other units per container)</th>
<th>Controlled Substance Content (Each Unit)</th>
<th>FOR DEA USE ONLY</th>
<th>DISPOSITION</th>
<th>QUANTITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The controlled substances surrendered in accordance with Title 21 of the Code of Federal Regulations, Section 1307.21, have been received in ___________ packages purporting to contain the drugs listed on this inventory and have been: **(1) Forwarded tape-sealed without opening; (2) Destroyed as indicated and the remainder forwarded tape-sealed after verifying contents; (3) Forwarded tape-sealed after verifying contents.

DATE: ____________________ DESTROYED BY: ____________________

** Strike out lines not applicable.

WITNESSED BY: ____________________

---

INSTRUCTIONS

1. List the name of the drug in column 1, the number of containers in column 2, the size of each container in column 3, and in column 4 the controlled substance content of each unit described in column 3, e.g., morphine sulfate tabs, 3 pills, 100 tabs, 1/4 gr. (0.6 mg.) or morphine citrate tabs, 1 pkg. 83 tabs, 12 gr. (32 mg.), etc.

2. All packages included on a single line should be identical in name, content and controlled substance strength.

3. Prepare this form in quadruplicate. Mail two (2) copies of this form to the Special Agent in Charge, under separate seal. Enclose one additional copy in the shipment with the drugs. Keep one copy for your records. One copy will be returned to you as a receipt. No further receipt will be furnished to you unless specifically requested. Any further inquiries concerning these drugs should be addressed to the DEA District Office which serves your area.

4. There is no provision for payment for drugs surrendered. This is merely a service rendered to registrants enabling them to clear their stocks and records of unwanted items.

5. Drugs should be shipped tape-sealed in padlocked boxes or certified mail (return receipt requested) to Special Agent in Charge, Drug Enforcement Administration, of the DEA District Office which serves your area.

---

PRIVACY ACT INFORMATION

AUTHORITY: Section 307 of the Controlled Substances Act of 1970 (PL 91-513). PURPOSE: To document the surrender of controlled substances which have been forwarded by registrants to DEA for disposal.

ROUTINE USES: This form is required by Federal Regulations for the surrender of unwanted Controlled Substances. Disclosures of information from this system are made to the following categories of users for the purposes stated:

A. Other Federal law enforcement and regulatory agencies for law enforcement and regulatory purposes.

B. State and local law enforcement and regulatory agencies for law enforcement and regulatory purposes.

C. Other individuals as disclosed pursuant to 21 CFR 312.3(a).

D. Under the Paperwork Reduction Act, a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to the Drug Enforcement Administration, FOI and Reports Management Section, Washington, D.C. 20537 and to the Office of Management and Budget, Paperwork Reduction Project no. 1117-0007, Washington, D.C. 20503.
REPORT OF THEFT OR LOSS OF CONTROLLED SUBSTANCES

Federal Regulations require registrants to submit a detailed report of any theft or loss of Controlled Substances to the Drug Enforcement Administration. Complete the front and back of this form in triplicate. Forward the original and duplicate copies to the nearest DEA Office. Retain the triplicate copy for your records. Some states may also require a copy of this report.

1. Name and Address of Registrant (include ZIP Code)
   | ZIP CODE |
   |          |

2. Phone No. (Include Area Code)

3. DEA Registration Number
   | 2 br. prefix | 7 digit suffix |
   |             |               |

4. Date of Theft or Loss

5. Principal Business of Registrant (Check one)
   - Pharmacy
   - Distributor
   - Practitioner
   - Morphine Program
   - Manufacturer
   - Hospital/Clinic

6. County in which Registrant is located

7. Was Theft reported to Police?
   - Yes
   - No

8. Name and Telephone Number of Police Department (Include Area Code)

9. Number of Thefts or Losses Registrant has experienced in the past 24 months

10. Type of Theft or Loss (Check one and complete items below as appropriate)
    - Night breakin
    - Employee pilferage
    - Customer theft
    - Lost in transit (Complete item 14)
    - Other (Explain)

11. If Armed Robbery, was anyone:
    - Killed? No Yes (How many)
    - Injured? No Yes (How many)

12. Purchase value to registrant of Controlled Substances taken?
    - $________

13. Were any pharmaceuticals or merchandise taken?
    - No
    - Yes (Est. Value)
        - $________

14. IF LOST IN TRANSIT, COMPLETE THE FOLLOWING:

   A. Name of Common Carrier
   B. Name of Consignee
   C. Consignee’s DEA Registration Number

   D. Was the caron received by the customer?
      - Yes
      - No

   E. If received, did it appear to be tampered with?
      - Yes
      - No

   F. Have you experienced losses in transit from this same carrier in the past?
      - No
      - Yes (How Many) __________

15. What identifying marks, symbols, or price codes were on the labels of these containers that would assist in identifying the products?

16. If Official Controlled Substance Order Forms (DEA-222) were stolen, give numbers.

17. What security measures have been taken to prevent future thefts or losses?

-------------------------------

PRIVACY ACT INFORMATION

AUTHORITY: Section 301 of the Controlled Substances Act of 1973 (PL 91-513).
PURPOSE: Report theft or loss of Controlled Substances.
ROUTINE USES: The Controlled Substances Act authorizes the production of special reports required for statistical and analytical purposes. Disclosures of information from this system are made to the following categories of users for the purposes stated:
A. Other Federal law enforcement and regulatory agencies for law enforcement and regulatory purposes.
B. State and local law enforcement and regulatory agencies for law enforcement and regulatory purposes.

EFFECT: Failure to report theft or loss of controlled substances may result in penalties under Section 402 and 401 of the Controlled Substances Act.

In accordance with the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this collection of information is 1117-0001. Public reporting burden for this collection of information is estimated to average 36 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.

FORM DEA - 106 (11-00) Previous editions obsolete
### LIST OF CONTROLLED SUBSTANCES LOST

<table>
<thead>
<tr>
<th>Trade Name of Substance or Preparation</th>
<th>Name of Controlled Substance in Preparation</th>
<th>Dosage Strength and Form</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examples:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Desoxyn</td>
<td>Methamphetamine Hydrochloride</td>
<td>5 mg Tablets</td>
<td>3 x 100</td>
</tr>
<tr>
<td>Demerol</td>
<td>Meperidine Hydrochloride</td>
<td>50 mg/ml Vial</td>
<td>5 x 30 ml</td>
</tr>
<tr>
<td>Robitussin A-C</td>
<td>Codains Phosphate</td>
<td>2 mg/cc Liquid</td>
<td>12 Pints</td>
</tr>
</tbody>
</table>

| 1. |                                            |                          |          |
| 2. |                                            |                          |          |
| 3. |                                            |                          |          |
| 4. |                                            |                          |          |
| 5. |                                            |                          |          |
| 6. |                                            |                          |          |
| 7. |                                            |                          |          |
| 8. |                                            |                          |          |
| 9. |                                            |                          |          |
| 10.|                                            |                          |          |
| 11.|                                            |                          |          |
| 12.|                                            |                          |          |
| 13.|                                            |                          |          |
| 14.|                                            |                          |          |
| 15.|                                            |                          |          |
| 16.|                                            |                          |          |
| 17.|                                            |                          |          |
| 18.|                                            |                          |          |
| 19.|                                            |                          |          |
| 20.|                                            |                          |          |
| 21.|                                            |                          |          |
| 22.|                                            |                          |          |
| 23.|                                            |                          |          |
| 24.|                                            |                          |          |
| 25.|                                            |                          |          |
| 26.|                                            |                          |          |
| 27.|                                            |                          |          |
| 28.|                                            |                          |          |
| 29.|                                            |                          |          |
| 30.|                                            |                          |          |
| 31.|                                            |                          |          |
| 32.|                                            |                          |          |
| 33.|                                            |                          |          |
| 34.|                                            |                          |          |
| 35.|                                            |                          |          |
| 36.|                                            |                          |          |
| 37.|                                            |                          |          |
| 38.|                                            |                          |          |
| 39.|                                            |                          |          |
| 40.|                                            |                          |          |
| 41.|                                            |                          |          |
| 42.|                                            |                          |          |
| 43.|                                            |                          |          |
| 44.|                                            |                          |          |
| 45.|                                            |                          |          |
| 46.|                                            |                          |          |
| 47.|                                            |                          |          |
| 48.|                                            |                          |          |
| 49.|                                            |                          |          |
| 50.|                                            |                          |          |

I certify that the foregoing information is correct to the best of my knowledge and belief.

<table>
<thead>
<tr>
<th>Signature</th>
<th>Title</th>
<th>Date</th>
</tr>
</thead>
</table>
DEPICTION of PAGE 1 of DEA FORM-222
U.S. OFFICIAL ORDER FORM - SCHEDULES I & II

See Reverse of PURCHASER’S Copy of Instructions
No order form may be issued for Schedule I and II substances unless a completed application form has been received, (21 CFR 1305.04).

TO:  (Name of Supplier)  STREET ADDRESS

CITY and STATE  DATE

TO BE FILLED IN BY SUPPLIER
SUPPLIERS DEA REGISTRATION No.

<table>
<thead>
<tr>
<th>LINE No.</th>
<th>No. of Packages</th>
<th>Size of Package</th>
<th>Name of Item</th>
<th>National Drug Code</th>
<th>Packages Shipped</th>
<th>Date Shipped</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

LAST LINE COMPLETED (MUST BE 10 OR LESS)
SIGNATURE OR PURCHASER OR ATTORNEY OR AGENT

Date Issued  DEA Registration No.  Name and Address of Registrant

Schedules

Registered as a  No. of this Order Form

DEA Form-222 (Oct. 1992)

U.S. OFFICIAL ORDER FORMS - SCHEDULES I & II
DRUG ENFORCEMENT ADMINISTRATION
SUPPLIER’S Copy 1

Note: The graphic illustrated above is not intended to be used as an actual order form.

2006 Edition
Page 47
# Form-224

## APPLICATION FOR REGISTRATION

Under the Controlled Substances Act

### INSTRUCTIONS

1. To apply by mail, complete this application. Keep a copy for your records.
2. Print clearly, using black or blue ink, or use a typewriter.
3. Mail this form to the address provided in Section 7 or use an insured envelope.
4. Include the correct payment amount. 
5. If you have any questions, call 000-000-0000 prior to submitting your application.
6. Save time—apply online at www.deadiversion.usdoj.gov

**IMPORTANT: DO NOT SEND THIS APPLICATION AND APPLY ONLINE.**

### REGISTRATION INFORMATION:

**$390.00**

FEE IS NON-REFUNDABLE

### SECTION 1

**APPLICANT IDENTIFICATION**

- Last Name (if registration is for individual) - OR - Business or Facility Name (if registration is for business entity)

- First Name (if registration is for individual)

- Business or Facility Name 2 (doing business as, continuation of business name, or name of fee exempt institution)

- Address Line 1 (street address)

- Address Line 2

- City

- State

- Zip Code

- Business Phone Number

- Business Fax Number

### SECTION 2

#### BUSINESS ACTIVITY

- Hospital/Clinic
- Ambulance Service
- Nursing Home
- Animal Shelter
- Central Fill Pharmacy
- Teaching Institution
- Retail Pharmacy
- Automated Dispensing System
- End-of-Life Care

### SECTION 3

**DRUG SCHEDULES**

Check all that apply

- Schedule II Narcotic
- Schedule II Non-Narcotic
- Schedule III Narcotic
- Schedule III Non-Narcotic
- Schedule IV
- Schedule V

- Check this box if you require official order forms for the purchase of schedule I narcotics/schedule II non-narcotic controlled substances

**NEW - Page 1**
SECTION 4

<table>
<thead>
<tr>
<th>STATE LICENSE(S)</th>
<th>YES</th>
<th>PENDING</th>
<th>NO</th>
<th>State License Number</th>
<th>State Controlled Substance License Number (if required)</th>
</tr>
</thead>
</table>

Be sure to include both state license numbers if applicable.

SECTION 5

**LIABILITY**

1. Has the applicant ever been convicted of a crime in connection with controlled substance(s) under state or federal law? [YES] [NO]

2. Has the applicant ever surrendered (for cause) or had a federal controlled substance registration revoked, suspended, restricted, or denied? [YES] [NO]

3. Has the applicant ever surrendered (for cause) or had a state professional license or controlled substance registration revoked, suspended, denied, restricted, or placed on probation? [YES] [NO]

4. If the applicant is a corporation (other than a corporation whose stock is owned and traded by the public), association, partnership, or pharmacy, has any officer, partner, stockholder, or proprietor ever been convicted of a crime in connection with controlled substance(s) under state or federal law, or ever surrendered, for cause, or had a federal controlled substance registration revoked, suspended, denied, restricted, or ever had a state professional license or controlled substance registration revoked, suspended, denied, restricted or placed on probation? [YES] [NO]

**EXPLANATION OF "YES" ANSWERS**

Applicants who have answered "YES" to any of the four questions above must provide a statement to explain such answers. Use this space or attach a separate sheet and return with application.

**SECTION 6**

**CERTIFICATION OF EXEMPTION**

From application fee

☐ Check this box if the applicant is a federal, state, or local government operated hospital, institution or official.

The undersigned hereby certifies that the applicant named herein is a federal, state or local government-operated hospital, institution or official, and is exempt from payment of the application fee.

Provide the name and phone number of the certifying official:

Signature of certifying official (other than applicant) __________________________

Date __________________________

Print or type name and title of certifying official __________________________

Telephone No. (required for verification) __________________________

**SECTION 7**

**METHOD OF PAYMENT**

☐ Check: [ ] American Express [ ] Discover [ ] Master Card [ ] Visa

Mail this form with payment to:

U.S. Department of Justice
Drug Enforcement Administration
P.O. Box 28083
Washington, DC 20038-8083

FEE IS NON-REFUNDABLE

**SECTION 8**

I certify that the foregoing information furnished on this application is true and correct.

Signature of applicant __________________________

Date __________________________

Print or type name and title of applicant __________________________

WARNING: Section 6402j(a)(4)(A) of Title 21, United States Code states that any person who knowingly or intentionally furnishes false or fraudulent information in this application is subject to imprisonment for not more than four years, a fine not more than $30,000, or both.

1. No registration will be issued unless a completed application form has been received (21 CFR 1301.13).
2. In accordance with the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this collection is 1117-0014. Public reporting burden for this collection of information is estimated to take 12 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.
3. The Drug Enforcement Administration (DEA) is required to furnish your Taxpayer Identification Number and Social Security Number on this application.
4. PRIVACY ACT INFORMATION

AUTHORITY: Section 304 and 309 of the Controlled Substances Act of 1970 (21 U.S.C. 864 and 869) (for personal use and for state and local law enforcement and regulatory purposes).

PURPOSE: To obtain information required to register persons under the Controlled Substances Act of 1970.

ROUTINE USES: The information is made available to the following categories of users for the purposes stated:

A. Other federal law enforcement and regulatory agencies for law enforcement and regulatory purposes.
B. State and local law enforcement and regulatory agencies for law enforcement and regulatory purposes.
C. Persons registered under the Controlled Substances Act (21 U.S.C. 864 and 869) for the purpose of verifying the registration of customers.
## Drug Schedules

Listed below are examples of the schedules with assigned drug code numbers. If you are in need of additional information, see 21 CFR 1306 or contact the DEA office serving your area.

### Schedule I

<table>
<thead>
<tr>
<th>Code</th>
<th>Narcotic Basic Classes</th>
</tr>
</thead>
<tbody>
<tr>
<td>0349</td>
<td>Codeine up to 90 mg plus other ingredients</td>
</tr>
<tr>
<td>0911</td>
<td>Dextropropoxyphene 50 mg plus other ingredients</td>
</tr>
<tr>
<td>0907</td>
<td>Hydromorphone up to 20 mg plus other ingredients</td>
</tr>
<tr>
<td>8014</td>
<td>Meperidine 10 mg plus other ingredients</td>
</tr>
</tbody>
</table>

### Schedule II

<table>
<thead>
<tr>
<th>Code</th>
<th>Narcotic Basic Classes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Dihydrocodeine 10 mg plus other ingredients</td>
</tr>
<tr>
<td>1222</td>
<td>Demerol 25 mg plus other ingredients</td>
</tr>
</tbody>
</table>

### Schedule III

<table>
<thead>
<tr>
<th>Code</th>
<th>Narcotic Basic Classes</th>
</tr>
</thead>
<tbody>
<tr>
<td>4008</td>
<td>Azaperone</td>
</tr>
</tbody>
</table>

### Schedule IV

<table>
<thead>
<tr>
<th>Code</th>
<th>Narcotic Basic Classes</th>
</tr>
</thead>
<tbody>
<tr>
<td>5210</td>
<td>Codeine Cough Preparation (200 mg/10 ml or 100 g)</td>
</tr>
</tbody>
</table>

### Non-Narcotic Basic Classes

<table>
<thead>
<tr>
<th>Code</th>
<th>Non-Narcotic Basic Classes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1020</td>
<td>Atenolol 500 mg plus other ingredients</td>
</tr>
</tbody>
</table>

---

**Notice to Registrants Making Payment by Check**

Authorization to Convert Your Check: If you send us a check to make your payment, your check will be converted into an electronic fund transfer. "Electronic fund transfer" is the term used to refer to this process in which we electronically instruct your financial institution to transfer funds from your account to ours, rather than processing your check. By sending your completed, signed check to us, you authorize us to post your check to our account using the account information from your check. If the electronic fund transfer cannot be processed for technical reasons, you authorize us to process the copy of your check.

Insufficient Funds: The electronic fund transfer from your account will usually occur within 24 hours, which is faster than a check is normally processed. Therefore, we must make sure there are sufficient funds available in your checking account when you send your check. If the electronic fund transfer cannot be completed because of insufficient funds, we may try to make the transfer up to two times.

Transaction Information: The electronic fund transfer from your account will show on the account statement you receive from your financial institution. However, the transfer may be in a different place on your statement than the place where your checks normally appear. For example, it may appear under "other withdrawals" or "other transactions." You will not receive your original check back from your financial institution. For security reasons, we will destroy your original check, but we will keep a copy of the check for record-keeping purposes.

Your Rights: You should contact your financial institution immediately if you believe that the electronic fund transfer reported on your account statement was not properly authorized or is otherwise incorrect. Consumers have protections under Federal law called the Electronic Funds Transfer Act for unauthorized or incorrect electronic fund transfers.
# RENEWAL APPLICATION FOR REGISTRATION

## Under the Controlled Substances Act

**INSTRUCTIONS**
1. To renew by mail complete this application. Keep a copy for your records.
2. Print clearly, using black or blue ink, or use a typewriter.
3. Section 5 should be completed only if your information has changed.
4. Mail this form to the address provided in Section 6 or use enclosed envelope.
5. Include the correct payment (check or money order payable to US Treasury). FEE IS NON-REFUNDABLE.
6. If you have any questions call 800-444-6666 prior to submitting your application.
7. Save time - renew online at www.deadiversion.usdoj.gov.

IMPORTANT: DO NOT SEND THIS APPLICATION AND RENEW ONLINE.

FEE IS NON-REFUNDABLE

### SECTION 1

<table>
<thead>
<tr>
<th>Drug Schedules</th>
<th>Schedule II Narcotic</th>
<th>Schedule III Narcotic</th>
<th>Schedule IV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Schedule II Non-Narcotic</td>
<td>Schedule III Non-Narcotic</td>
<td>Schedule V</td>
</tr>
</tbody>
</table>

**Check all that apply**

### SECTION 2

Check this box if you need official order forms for the purchase of schedule II narcotic/schedule III non-narcotic controlled substances.

### SECTION 3

**STATE LICENSE(S)**

- [ ] YES
- [ ] NO

Be sure to include both state license numbers if applicable.

**State License Number**

**State Controlled Substance License Number (if required)**

### LIABILITY

**IMPORTANT:** If you answered YES to these question(s) on previous application, you must continue to answer yes and provide a statement to explain.

**All questions in this section must be answered.**

- [ ] YES
- [ ] NO

### SECTION 4

**EXPLANATION OF "YES" ANSWERS**

Applicants who have answered YES to questions B, C, D, or E above must provide a statement to explain each answer.

Use this space or attach a separate sheet and return with application.

**Nature of Incident:**

**Result of Incident:**

---

2006 Edition

Page 52
Form-224a
APPLICATION FOR RENEWAL
Supplementary Instructions and Information

ADDITIONAL INSTRUCTIONS

SECTION 1. DRUG SCHEDULES - Applicants should check all drug schedules to be handled. However, applicants must comply with state requirements. Federal registration does not override state restrictions. Check the order form box only if you intend to purchase or transfer schedule II controlled substances.

SECTION 2. ORDER FORMS - Order forms will be mailed to the registrant by the DEA. Order forms are required for all applications. Applications should be sent to the DEA by certified mail.

SECTION 3. STATE LICENSE(S) - Federal registration by DEA is based upon the applicant's compliance with applicable state and local laws. State licenses are required for the sale, purchase, or manufacture of controlled substances. Applicants should check the local state licensing authority prior to applying for federal registration. If your state requires a separate controlled substance number, provide that number on this application. If a state license has not yet been issued, indicate "Pending." If state licensing authority is not required, indicate "Not Required." Federal registration information is mandatory pursuant to the Drug Dealer Registration Act of 1970.

SECTION 4. LIABILITY - Applicants must answer all four questions for the application to be accepted for processing. If your state requires a fee, you should provide the reference of the fee payment to the DEA. The fee paid must be ascertained. If there are any questions about the fee, you should contact the DEA.

SECTION 5. APPLICANT IDENTIFICATION - Entry of missing data or corrections. Only the applicant may sign and process the application. If an error is found in previously processed registration information, such as name change, address correction, or new or phone numbers, the applicant must file the correction form. If necessary, the correction form must be completed in accordance with the DEA. New applicants must file the correction form with the DEA.

SECTION 6. METHOD OF PAYMENT - Dependent upon the method of payment. Make checks payable to Drug Enforcement Administration, DEA Office. Third-party checks or drafts on foreign banks will not be accepted. DEER Registering agents can be reimbursed for the cost of the registration application.

SECTION 7. CERTIFICATE OF EXEMPTION - Exemption from payment of registration fees is limited to federal, state or local government operated hospitals, institutions and offices. The applicant must submit a copy of the certificate of exemption. The signature, authority to do business and telephone number of the certifying official (other than the applicant) must be provided.

SECTION 8. APPLICANT'S SIGNATURE - Must be the original signature (not a copy) of the applicant.

CONTACT INFORMATION

1. INTERNET:

2. TELEPHONE:

3. WRITTEN INQUIRIES: Drug Enforcement Administration

4. DEA OFFICES: DEA Offices are listed below (800, 877, and 888 are toll-free numbers).

ATLANTA DIVISION OFFICE
ATTN: Registration
75 Spring Street, NW, Suite 600
Atlanta, GA 30303

Georgia (800) 866-9438
North Carolina (888) 210-2864
South Carolina (800) 533-9983
Tennessee (888) 216-7886

BOSTON DIVISION OFFICE
JFK Federal Building
15 Newbury Street, Room 400
Boston, MA 02210-3311

Connecticut (203) 557-2300
Massachusetts (877) 272-5174
New Hampshire (800) 557-3488
Rhode Island (888) 272-5174
Vermont (800) 557-2200

CARIBBEAN DIVISION OFFICE
P.O. Box 2167
San Juan, PR 00902-2167

Puerto Rico (787) 775-7788
U.S. Virgin Islands (787) 775-7788

CHICAGO DIVISION OFFICE
Kearny Federal Building
230 S. Dearborn Street, Suite 1200
Chicago, IL 60604

Illinois (312) 555-1224
Indiana (312) 555-1338
Minnesota (612) 555-1216
North Dakota (701) 555-1200
Wisconsin (414) 555-1230

DALLAS DIVISION OFFICE
10100 Technology Blvd., East
Dallas, TX 75260

Oklahoma (888) 320-1720
Texas (Northern) (800) 320-1720

DENVER DIVISION OFFICE
115 Pennsylvania Drive, East
Englewood, CO 80112

Colorado (303) 920-0900
Montana (800) 320-9850
Utah (800) 320-9850
Wyoming (800) 320-9850

DEPTON DIVISION OFFICE
411 Howard Street
Detroit, MI 48226

Kentucky (800) 230-6944
Michigan (800) 230-6944
Ohio (800) 230-6944

EL PASO DIVISION OFFICE
El Paso Federal Courthouse
400 South Mesa St., Suite 2000
El Paso, TX 79901

New Mexico (505) 835-0014

HOUSTON DIVISION OFFICE
1433 West Loop South, Suite 100
Houston, TX 77027-4500

Texas (866) 782-7878

LOS ANGELES DIVISION OFFICE
226 East Temple Street, 20th Floor
Los Angeles, CA 90012

California (800) 320-1720

MIAMI DIVISION OFFICE
5400 N.W. 53rd Street
Miami, FL 33163

Florida (800) 500-4630

NEWARK DIVISION OFFICE
15 Mulberry Street, 2nd Floor
Newark, NJ 07102

New Jersey (800) 320-1720

NEW ORLEANS DIVISION OFFICE
203 N. 12th Street
New Orleans, LA 70117

Louisiana (800) 514-9251

NEW YORK DIVISION OFFICE
811 Avenue of the Americas
New York, NY 10017

New York (800) 882-1071

RENEWAL INST. - Page 3

Drug Enforcement Administration
Practitioner’s Manual

PHILADELPHIA DIVISION OFFICE
William J. Green Federal Building
900 Arch Street, Room 1022
Philadelphia, PA 19107

Pennsylvania (888) 303-2331

PHOENIX DIVISION OFFICE
3007, 2nd Street, Suite 301
Phoenix, AZ 85012

Arizona (800) 303-2331

SANDIEGO DIVISION OFFICE
4500 Westgate Avenue
San Diego, CA 92153-1937

California (800) 303-2331

SAN FRANCISCO DIVISION OFFICE
450 Golden Gate Avenue, 14th Floor
P.O. Box 50055
San Francisco, CA 94102

California (800) 303-2331

SEATTLE DIVISION OFFICE
802 Second Avenue, West
Seattle, WA 98101

Seattle (800) 303-2331

ST. LOUIS DIVISION OFFICE
317 South 11th Street
St. Louis, MO 63103

Missouri (800) 303-2331

WASHINGTON, D.C. DIVISION OFFICE
700 K Street, NW, Suite 1000
Washington, D.C. 20004

Washington (800) 303-2331

DEER Registering agents can be reimbursed for the cost of the registration application.
**Drug Enforcement Administration**

**Practitioner’s Manual**

---

### SCHEDULE I

**NARCOTIC & NON-NARCOTIC BASIC CLASSES**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetophene</td>
<td>0110</td>
</tr>
<tr>
<td>Acriflavine</td>
<td>0151</td>
</tr>
<tr>
<td>Allopurinol</td>
<td>0620</td>
</tr>
<tr>
<td>Alprazolam</td>
<td>0752</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Alprazolam Hydrochloride (except LAAM)</td>
<td>0753</td>
</tr>
<tr>
<td>Form-363 APPLICATION FOR REGISTRATION Under the Narcotic Addict Treatment Act of 1974</td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>INSTRUCTIONS</strong></td>
<td><strong>REGISTRATION INFORMATION:</strong></td>
</tr>
<tr>
<td>1. To apply by mail complete this application. Keep a copy for your records.</td>
<td></td>
</tr>
<tr>
<td>2. Print clearly, using black or blue ink, or use a typewriter.</td>
<td></td>
</tr>
<tr>
<td>3. Section 1 should be completed only if your information has changed.</td>
<td></td>
</tr>
<tr>
<td>4. Mail this form to the address provided in Section II or use enclosed envelope.</td>
<td></td>
</tr>
<tr>
<td>5. Include the correct payment amount. FEE IS NON-REFUNDABLE.</td>
<td></td>
</tr>
<tr>
<td>6. If you have any questions, contact 800-882-9539 prior to submitting your application.</td>
<td></td>
</tr>
<tr>
<td>7. Save time - apply online at <a href="http://www.deadiversion.usdoj.gov">www.deadiversion.usdoj.gov</a>.</td>
<td></td>
</tr>
<tr>
<td>IMPORTANT: DO NOT SEND THIS APPLICATION AND APPLY ONLINE.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Fee for 1 year is $130</td>
<td></td>
</tr>
<tr>
<td>FEE IS NON-REFUNDABLE</td>
<td></td>
</tr>
</tbody>
</table>

**SECTION 1 APPLICANT IDENTIFICATION**

<table>
<thead>
<tr>
<th>Business or Facility Name (if registration is for business entity or is fee exempt)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Business or Facility Name 2 (&quot;doing business as&quot;, continuation of business name, or name of fee exempt institution)</td>
</tr>
<tr>
<td>Address Line 1 (street address)</td>
</tr>
<tr>
<td>Address Line 2</td>
</tr>
<tr>
<td>City</td>
</tr>
<tr>
<td>Business Phone Number</td>
</tr>
</tbody>
</table>

**DEBT COLLECTION INFORMATION**

| Tax Identification Number |

See note #3 on bottom of page 2.

**SECTION 2 BUSINESS ACTIVITY**

Check one box only

- NTP - Maintenance
- NTP - Detoxification
- NTP - Maintenance and Detoxification
- NTP - Compounder / Maintenance
- NTP - Compounder / Detoxification
- NTP - Compounder / Maintenance and Detoxification

**SECTION 3 DRUG SCHEDULES**

Check all that apply

- Schedule II
- Schedule III

**SECTION 4 FDA PERMIT**

| Mandatory for approval | FDA Number |

| YES | PENDING | NO |

**STATE LICENSE(S)**

| YES, I have a license | State License Number |

| NOT REQUIRED by this state | |

NEW - Page 1
SECTION 6
LIABILITY

1. Has the applicant ever been convicted of a crime in connection with controlled substances under state or federal law?
   □ Yes □ No

2. Has the applicant ever surrendered (for cause) or had a federal controlled substance registration revoked, suspended, restricted, or denied?
   □ Yes □ No

3. Has the applicant ever surrendered (for cause) or had a state professional license or controlled substance registration revoked, suspended, restricted, or placed on probation? Is any such action pending?
   □ Yes □ No

4. If the applicant is a corporation (other than a corporation whose stock is owned and traded by the public), association, partnership, or pharmacy, has any officer, partner, stockholder, or proprietor been convicted of a crime in connection with controlled substances under state or federal law, or ever surrendered, for cause, or had a federal controlled substance registration revoked, suspended, restricted, denied, or ever had a state professional license or controlled substance registration revoked, suspended, denied, restricted or placed on probation?
   □ Yes □ No

EXPLANATION OF "YES" ANSWERS

Applicants who have answered "YES" to any of the four questions above must provide a statement to explain such answers.

Use this space or attach a separate sheet and return with application.

Result of incident:

SECTION 7
CERTIFICATION OF EXEMPTION from application fee

☐ Check this box if the applicant is a federal, state, or local government-operated narcotic treatment program.

The undersigned hereby certifies that the applicant named herein is a federal, state or local government-operated narcotic treatment program, and is exempt from payment of the application fee.

Provide the name and phone number of the certifying official:

Signature of certifying official (other than applicant):

Date:

Print or type name and title of certifying official:

Telephone No. (required for verification):

SECTION 8
METHOD OF PAYMENT

☐ Check Make check payable to Drug Enforcement Administration

See page 3 of Instructions for Important Information.

Mail this form with payment to:

U.S. Department of Justice
Drug Enforcement Administration
P.O. Box 28083
Washington DC 20028-8083

FEE IS NON-REFUNDABLE

SECTION 9

I certify that the foregoing information furnished on this application is true and correct.

Signature of applicant:

Date:

Print or type name and title of applicant:

WARNING: Section 843(a)(4)(A) of Title 21, United States Code, states that any person who knowingly or intentionally furnishes false or fraudulent information in the application is subject to imprisonment for not more than four years, a fine of not more than $30,000, or both.

1. No registration will be issued unless a completed application form has been received (21 CFR 1301.13).

2. In accordance with the Pay-as-you-go (PAYG) requirement of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this collection is 1111-0015. Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.

3. The Privacy Act Information Collection Statement (21 CFR 1304.15) requires that you furnish your taxpayer identifying number and/or social security number on this application. This number is required for claim certification purposes and it will become uncollectible.

4. PRIVACY ACT INFORMATION

AUTHORITY: Section 302 and 303 of the Controlled Substances Act of 1970 (PL 91-513) and Drug Enforcement Improvements Act of 1996 (PL 104-154) (for taxpayer identifying number and/or social security number).

PURPOSE: To obtain information required to register applicants pursuant to the Controlled Substances Act of 1970.

ROUTINE USES: The Controlled Substances Act Registration Records provide special reports as required for statistical analytical purposes. Disclosures of information from this system are made to the following categories of users for the purposes stated:

A. Other federal law enforcement and regulatory agencies for law enforcement and regulatory purposes.

B. State and local law enforcement and regulatory agencies for law enforcement and regulatory purposes.

C. Persons registered under the Controlled Substances Act (PL 91-513) for the purpose of verifying the registration of customers.

EFFECT: Failure to complete form will preclude processing of the application.
| Form-363 APPLICATION FOR REGISTRATION  |
| Supplementary Instructions and Information |
| ADDITIONAL INSTRUCTIONS |
| SECTION 1. APPLICANT IDENTIFICATION - Information must be typed or printed in the blocks provided to help reduce data entry errors. Fee exempt applicant should list the name and address of the fee exempt institution. A physical address is required; a post office box may be included after the street address. Applicant must enter a valid tax identification number (TIN). Debt collection information is mandatory pursuant to the Debt Collection Improvement Act of 1996. |
| SECTION 2. BUSINESS ACTIVITY. Indicate only one. |
| SECTION 3. DRUG SCHEDULES - Applicant should check all drug schedules to be handled. However, applicant must still comply with state requirements; federal registration does not override state restrictions. Check the order form box only if you intend to purchase or to transfer schedule II controlled substances. Order forms will be mailed to the registered address following issuance of a Certificate of Registration. |
| SECTION 4. FDA PERMIT - Authorization by the Food & Drug Administration is mandatory for DEA Registration approval. Enter the status of your FDA authorization and the FDA number. |
| SECTION 5. STATE LICENSE(S) - Federal registration by DEA is based upon the applicant’s compliance with applicable state and local laws. Applicant should contact the local state licensing authority prior to completing this application. Check that you are currently authorized by the state and provide your state license number. If state licensing is not required, indicate “Not required by this state”. |
| SECTION 6. LIABILITY - Applicant must answer all four questions for the application to be accepted for processing. If you answered “Yes” to any question, provide an explanation in the space provided. If additional space is required, you may attach a separate sheet of paper. |
| SECTION 7. CERTIFICATE OF EXEMPTION - Exemption from payment of application fee is limited to federal, state or local government-operated narcotic treatment program. The applicant’s superior or agency officer must certify exempt status. The signature, authority title, and telephone number of the certifying official (other than the applicant) must be provided. |
| SECTION 8. METHOD OF PAYMENT - Indicate the desired method of payment. Make checks payable to Drug Enforcement Administration. Third-party checks or checks drawn on foreign banks will not be accepted. FEES ARE NON-REFUNDABLE. |
| SECTION 9. APPLICANT’S SIGNATURE - Must be the original signature (in ink) of the applicant. |

**Notice to Registrants Making Payment by Check**

Authorization to Convert Your Check: If you send us a check to make your payment, your check will be converted into an electronic fund transfer. "Electronic fund transfer" is the term used to refer to the process in which we electronically instruct your financial institution to transfer funds from your account to our account, rather than processing your check. By sending your completed, signed check to us, you authorize us to copy your check and to use the account information from your check to make an electronic fund transfer from your account for the same amount as the check. If the electronic fund transfer cannot be processed for technical reasons, you authorize us to process the copy of your check.

Insufficient Funds: The electronic funds transfer from your account will usually occur with 24 hours, which is faster than a check is normally processed. Therefore, make sure there are sufficient funds available in your checking account when you send us your check. If the electronic funds transfer cannot be completed because of insufficient funds, we may try to make the transfer up to two times.

Transaction Information: The electronic fund transfer from your account will be on the account statement you receive from your financial institution. However, the transfer may be in a different place on your statement than the place where your checks normally appear. For example, it may appear under “other withdrawals” or “other transactions.” You will not receive your original check back from your financial institution. For security reasons, we will destroy your original check, but we will keep a copy of the check for record-keeping purposes.

Your Rights: You should contact your financial institution immediately if you believe that the electronic fund transfer reported on your account statement was not properly authorized or is otherwise incorrect. Consumers have protections under Federal law called the Electronic Fund Transfer Act for an unauthorized or incorrect electronic fund transfer.
### APPLICATION FOR REGISTRATION

**Supplementary Instructions and Information**

<table>
<thead>
<tr>
<th>CONTACT INFORMATION</th>
<th>1. INTERNET: Information can be found on our web site at <a href="http://www.deadiversion.usdoj.gov">www.deadiversion.usdoj.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2. TELEPHONE: Headquarters Call Center: (800) 882-9639</td>
</tr>
<tr>
<td></td>
<td>3. WRITTEN INQUIRIES: Drug Enforcement Administration P.O. Box 20093 Washington DC 20038-8083</td>
</tr>
<tr>
<td></td>
<td>4. DEA OFFICES: DEA Offices are listed below (800, 877, and 888 are toll-free numbers).</td>
</tr>
</tbody>
</table>

### DEA OFFICES

<table>
<thead>
<tr>
<th>ATLANTA DIVISION OFFICE</th>
<th>DETROIT DIVISION OFFICE</th>
<th>PHILADELPHIA DIVISION OFFICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATTN: Registration</td>
<td>Kentucky</td>
<td>William J. Green Federal Building</td>
</tr>
<tr>
<td>75 Spring Street, SW, Suite 800</td>
<td>(800) 230-8844</td>
<td>600 Arch Street, Room 10224</td>
</tr>
<tr>
<td>Atlanta, GA 30303</td>
<td>Michigan</td>
<td>Philadelphia, PA 19106</td>
</tr>
<tr>
<td>Georgia (888) 869-9935</td>
<td>Ohio</td>
<td>Delaware (888) 393-8231</td>
</tr>
<tr>
<td>North Carolina (888) 219-9869</td>
<td>(800) 230-8844</td>
<td>Pennsylvania (888) 393-8231</td>
</tr>
<tr>
<td>South Carolina (888) 533-8983</td>
<td>(800) 230-8844</td>
<td></td>
</tr>
<tr>
<td>Tennessee (888) 219-7998</td>
<td>New Mexico</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BOSTON DIVISION OFFICE</th>
<th>HOUSTON DIVISION OFFICE</th>
<th>SAN FRANCISCO DIVISION OFFICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>JFK Federal Building</td>
<td>1433 West Loop South, Suite 600</td>
<td>4500 Golden Gate Avenue, 14th Floor</td>
</tr>
<tr>
<td>15 New Sudbury Street, Room E400</td>
<td>Houston, TX 77027-9506</td>
<td>P.O. Box 36035</td>
</tr>
<tr>
<td>Boston, MA 02203-0131</td>
<td>Texas (S. &amp; Central)</td>
<td>San Francisco, CA 94102</td>
</tr>
<tr>
<td>Connecticut (617) 557-2200</td>
<td>(800) 743-0595</td>
<td>California (Northern) (888) 304-3251</td>
</tr>
<tr>
<td>Maine (888) 272-5174</td>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Massachusetts (617) 557-2460</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Hampshire (888) 272-5174</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhode Island (617) 557-2200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vermont (888) 272-6174</td>
<td>Florida</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(305) 590-4890</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CARIBBEAN DIVISION OFFICE</th>
<th>MIAMI DIVISION OFFICE</th>
<th>SEATTLE DIVISION OFFICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. Box 2167</td>
<td>8400 N.W. 83rd Street</td>
<td>400 Second Avenue, West</td>
</tr>
<tr>
<td>San Juan, PR 00922-2167</td>
<td>Miami, FL 33166</td>
<td>Seattle, WA 98119</td>
</tr>
<tr>
<td>Puerto Rico (787) 775-1766</td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. Virgin Islands (787) 775-1766</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CHICAGO DIVISION OFFICE</th>
<th>MIAMI DIVISION OFFICE</th>
<th>SEATTLE DIVISION OFFICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Klucynski Federal Building</td>
<td>8400 N.W. 83rd Street</td>
<td>400 Second Avenue, West</td>
</tr>
<tr>
<td>230 S. Dearborn Street, Suite 1200</td>
<td>Miami, FL 33166</td>
<td>Seattle, WA 98119</td>
</tr>
<tr>
<td>Chicago, IL 60604</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Illinois (312) 353-1234</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indiana (312) 353-1236</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minnesota (312) 353-9166</td>
<td></td>
<td></td>
</tr>
<tr>
<td>North Dakota (312) 353-9166</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wisconsin (312) 353-1236</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DALLAS DIVISION OFFICE</th>
<th>MIAMI DIVISION OFFICE</th>
<th>SEATTLE DIVISION OFFICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>10160 Technology Blvd., East</td>
<td>8400 N.W. 83rd Street</td>
<td>400 Second Avenue, West</td>
</tr>
<tr>
<td>Dallas, TX 75220</td>
<td>Miami, FL 33166</td>
<td>Seattle, WA 98119</td>
</tr>
<tr>
<td>Oklahoma (888) 336-4704</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Texas (Northern) (888) 336-4704</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DENVER DIVISION OFFICE</th>
<th>MIAMI DIVISION OFFICE</th>
<th>SEATTLE DIVISION OFFICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>115 Inverness Drive, East</td>
<td>8400 N.W. 83rd Street</td>
<td>400 Second Avenue, West</td>
</tr>
<tr>
<td>Englewood, CO 80112</td>
<td>Miami, FL 33166</td>
<td>Seattle, WA 98119</td>
</tr>
<tr>
<td>Colorado (800) 326-6900</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Montana (800) 326-6900</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Utah (800) 326-6900</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wyoming (800) 326-6900</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NEW INST - Page 4**

**2006 Edition**

**Page 59**
**RENEWAL APPLICATION FOR REGISTRATION**

Under the Narcotic Addict Treatment Act of 1974

**INSTRUCTIONS**

1. To apply by mail complete this application. Keep a copy for your records.
2. Print clearly, using black or blue ink, or use a typewriter.
3. Section 1 should be completed only if your information has changed.
4. Mail this form to the address provided in Section 7 or use standard-size envelope.
5. Include the correct payment amount. FEE IS NON-REFUNDABLE.
6. If you have any questions contact (800) 852-6236 prior to submitting your application.
7. Save time - renew online at www.deadiversion.usdoj.gov.

**IMPORTANT:** DO NOT SEND THIS APPLICATION AND APPLY ONLINE.

**REGISTRATION INFORMATION:**

DEA #

REGISTRATION EXPIRES

**FEE IS NON-REFUNDABLE**

### SECTION 1

**APPLICANT IDENTIFICATION**

Business or Facility Name (if registration is for business entity or is fee exempt)

Business or Facility Name 2 ("doing business as", continuation of business name, or name of fee exempt institution)

Address Line 1 (street address)

Address Line 2

City  
State  
Zip Code

Business Phone Number

Business Fax Number

**DEBT COLLECTION INFORMATION**

Tax Identification Number

See note #3 on bottom of page 2.

### SECTION 2

**DRUG SCHEDULES**

- [ ] Schedule II
- [ ] Schedule III

Check all that apply

- [ ] Check this box if you require official order forms - for purchase or transfer of schedule I controlled substances.

### SECTION 3

**FDA PERMIT**

- [ ] Yes
- [ ] Pending
- [ ] No

Mandatory for approval

FDA Number

### SECTION 4

Are you currently authorized by the Food and Drug Administration for the business activity described in this application?

**STATE LICENSE(S)**

- [ ] Yes, I have a license
- [ ] Not required by this state

State License Number
### SECTION 5

#### LIABILITY

1. Has the applicant ever been convicted of a crime in connection with controlled substances under state or federal law? **YES** | **NO**

2. Has the applicant ever surrendered (for cause) or had a federal controlled substance registration revoked, suspended, restricted, or denied?  
   [ ]

3. Has the applicant ever surrendered (for cause) or had a state professional license or controlled substance registration revoked, suspended, denied, restricted, or placed on probation? Is any such action pending?  
   [ ]

4. If the applicant is a corporation (other than a corporation whose stock is owned and traded by the public), association, partnership, or pharmacy, has any officer, partner, stockholder, or proprietor been convicted of a crime in connection with controlled substances under state or federal law, or ever surrendered, for cause, or had a federal controlled substance registration revoked, suspended, restricted, denied, or ever had a state professional license or controlled substance registration revoked, suspended, denied, restricted, or placed on probation?  
   [ ]

#### IMPORTANT:

All questions in this section must be answered.

---

**EXPLANATION OF "YES" ANSWERS**

Applicants who have answered "YES" to any of the four questions above must provide a statement to explain such answers.

Use this space or attach a separate sheet and return with application.

**DATE(S) OF INCIDENT:**  
**LOCATION(S) OF INCIDENT:**

**NATURE OF INCIDENT:**

**RESULT OF INCIDENT:**

---

### SECTION 6

**CERTIFICATION OF EXEMPTION from application fee**

[ ] Check box if the applicant is a federal, state, or local government-operated narcotic treatment program.  

The undersigned hereby certifies that the applicant named herein is a federal, state or local government-operated narcotic treatment program, and is exempt from payment of the application fee.

**Signature of certifying official (other than applicant):**  
**Date:**

Print or type name and title of certifying official

**Date:**  
**Telephone No. (required for verification):**

---

### SECTION 7

**METHOD OF PAYMENT**

[ ] Check  
Make check payable to: Drug Enforcement Administration  
See page 3 of instructions for important information.

[ ] American Express  [ ] Discover  [ ] Master Card  [ ] Visa

Credit Card Number:  
Expiration Date:  

[ ] Sign if paying by credit card

**Signature of Card Holder:**  
**Printed Name of Card Holder:**

---

### SECTION 8

I certify that the following information furnished on this application is true and correct.

**Signature of applicant:**  
**Date:**

Print or type name and title of applicant

---

1. A signature will be required unless a completed application form has been received (21 CFR 1301.13).

2. In accordance with the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this collection is 1117-0005. Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, gathering data, and completing and reviewing the collection of information.

3. The Debt Collection Improvement Act of 1996 (PL 104-134) requires that you furnish your Taxpayer Identification Number and/or Social Security Number on this application.

4. PRIVACY ACT INFORMATION  
   **AUTHORITY:** Section 302 and 303 of the Controlled Substances Act of 1970 (PL 91-513) and Debt Collection Improvement Act of 1996 (PL 104-134) for taxpayer identification number and/or social security number.

   **PURPOSE:** To obtain information required to register applicants pursuant to the Controlled Substances Act of 1970.

   **ROUTINE USES:** The Controlled Substances Act Registration Records produces special reports as required for statistical analytical purposes. Disclosure of information from this system is made to the following categories of users for the purposes stated:

   A. Other federal law enforcement and regulatory agencies for law enforcement and regulatory purposes.

   B. State and local law enforcement and regulatory agencies for law enforcement and regulatory purposes.

   C. Persons registered under the Controlled Substances Act (PL 91-513) for the purpose of verifying the registration of customers.

   Failure to complete form will result in processing of the application.

   **EFFECT:**

---

2006 Edition
Page 61
**APPLICATION FOR RENEWAL**

**Supplementary Instructions and Information**

**SECTION 1**  **ADDITIONAL INSTRUCTIONS**

**APPLICATION IDENTIFICATION** - Entry of missing data or correction of errors must be typed or printed in the blocks provided to help reduce data entry errors. Enter changes in previously provided registration information, such as name change, address correction, or new phone number. Fee exempt applicant should list the name and address of the fee exempt institution.

A physical address is required; a post office box may be included after the street address.

Applicant should ensure that the tax identification number (TIN) on record is correct. *Debt collection information is mandatory pursuant to the Debt Collection Improvement Act of 1996.*

**SECTION 2**  **DRUG SCHEDULES** - Applicant should check all drug schedules to be handled. However, applicants must still comply with state requirements; federal registration does not override state restrictions.

Check the order form box only if you intend to purchase or to transfer schedule II controlled substances. Order forms will be mailed to the registered address following issuance of a Certificate of Registration renewal.

**SECTION 3**  **FDA PERMIT** - Authorization by the Food & Drug Administration is mandatory for DEA Registration approval. Enter the status of your FDA authorization and the FDA number.

**SECTION 4**  **STATE LICENSE(S)** - Federal registration by DEA is based upon the applicant's compliance with applicable state and local laws.

Applicant should contact the local state licensing authority prior to completing this application. Check that you are currently authorized by the state and provide your state license number. If state licensing is not required, indicate "Not required by this state".

**SECTION 5**  **LIABILITY** - Applicant must answer all four questions for the application to be accepted for processing.

If you answered "Yes" to any question, provide an explanation in the space provided.

If additional space is required, you may attach a separate sheet of paper.

**SECTION 6**  **CERTIFICATE OF EXEMPTION** - Exemption from payment of application fee is limited to federal, state or local government-operated narcotic treatment program.

The applicant's superior or agency officer must certify exempt status. The signature, authority title, and telephone number of the certifying official (other than the applicant) must be provided.

**SECTION 7**  **METHOD OF PAYMENT** - Indicate the desired method of payment. Make checks payable to "Drug Enforcement Administration". Third-party checks or checks drawn on foreign banks will not be accepted.

**FEES ARE NON-REFUNDABLE**

**SECTION 8**  **APPLICANT'S SIGNATURE** - Must be the original signature (in ink) of the applicant.

---

**Notice to Registrants Making Payment by Check**

*Authorization to Convert Your Check:* If you send us a check to make your payment, your check will be converted into an electronic fund transfer. "Electronic fund transfer" is the term used to refer to the process in which we electronically instruct your financial institution to transfer funds from your account to our account, rather than processing your check. By sending your completed, signed check to us, you authorize us to copy your check and to use the account information from your check to make an electronic fund transfer from your account for the same amount as the check. If the electronic fund transfer cannot be processed for technical reasons, you authorize us to process the copy of your check.

*Insufficient Funds:* The electronic funds transfer from your account will usually occur with 24 hours, which is faster than a check is normally processed. Therefore, make sure there are sufficient funds available in your checking account when you send us your check. If the electronic funds transfer cannot be completed because of insufficient funds, we may try to make the transfer up to two times.

*Transaction Information:* The electronic fund transfer from your account will be on the account statement you receive from your financial institution. However, the transfer may be in a different place on your statement than the place where your checks normally appear. For example, it may appear under "other withdrawals" or "other transactions." You will not receive your original check back from your financial institution. For security reasons, we will destroy your original check, but we will keep a copy of the check for record-keeping purposes.

*Your Rights:* You should contact your financial institution immediately if you believe that the electronic fund transfer reported on your account statement was not properly authorized or is otherwise incorrect. Consumers have protections under Federal law called the Electronic Fund Transfer Act for an unauthorized or incorrect electronic fund transfer.

**RENEWAL INST. - Page 3**

---

**2006 Edition**

**Page 62**
### Drug Enforcement Administration

**Practitioner’s Manual**

---

#### Form-363a

**APPLICATION FOR RENEWAL**

Supplementary Instructions and Information

<table>
<thead>
<tr>
<th>CONTACT INFORMATION</th>
<th>1. INTERNET: Information can be found on our web site at <a href="http://www.deadiversion.usdoj.gov">www.deadiversion.usdoj.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2. TELEPHONE: Headquarters Call Center: (800) 882-9539</td>
</tr>
<tr>
<td></td>
<td>3. WRITTEN INQUIRIES: Drug Enforcement Administration</td>
</tr>
<tr>
<td></td>
<td>P.O. Box 20083</td>
</tr>
<tr>
<td></td>
<td>Washington, DC 20038-8083</td>
</tr>
<tr>
<td></td>
<td>4. DEA OFFICES: DEA Offices are listed below (800, 877, and 888 are toll-free numbers).</td>
</tr>
</tbody>
</table>

**ATLANTA DIVISION OFFICE**

ATTN: Registration

75 Spring Street, SW, Suite 800

Atlanta, GA 30303

- Georgia: (866) 869-9036
- North Carolina: (888) 219-8669
- South Carolina: (866) 533-0936
- Tennessee: (888) 219-7899

**BOSTON DIVISION OFFICE**

JFK Federal Building

15 New Sudbury Street, Room E400

Boston, MA 02203-0131

- Connecticut: (817) 557-2200
- Maine: (888) 272-5174
- Massachusetts: (817) 557-2460
- New Hampshire: (817) 272-5174
- Rhode Island: (817) 557-2200
- Vermont: (888) 272-5174

**CARIBBEAN DIVISION OFFICE**

P.O. Box 2167

San Juan, PR 00922-2167

- Puerto Rico: (877) 775-1768
- U.S. Virgin Islands: (877) 775-1766

**CHICAGO DIVISION OFFICE**

Kluczynski Federal Building

230 S. Dearborn Street, Suite 1200

Chicago, IL 60604

- Illinois: (312) 353-1234
- Indiana: (312) 353-1236
- Minnesota: (312) 353-9166
- North Dakota: (312) 353-9165
- Wisconsin: (312) 353-1235

**DALLAS DIVISION OFFICE**

10160 Technology Blvd., East

Dallas, TX 75220

- Oklahoma (866) 336-4704
- Texas (Northern): (866) 235-4704

**DENVER DIVISION OFFICE**

115 Inverness Dr. E.

Englewood, CO 80112

- Colorado: (800) 326-8900
- Montana: (800) 326-8900
- Utah: (800) 326-8900
- Wyoming: (800) 326-8900

**DETROIT DIVISION OFFICE**

431 Howard Street

Detroit, MI 48226

- Kentucky: (800) 230-6844
- Michigan: (800) 230-6844
- Ohio: (800) 230-6844

**EL PASO DIVISION OFFICE**

El Paso Federal Justice Center

600 South Mesa Hills Drive, Suite 2000

El Paso, TX 79912

- New Mexico: (815) 832-6014

**HOUSTON DIVISION OFFICE**

1433 West Loop South, Suite 600

Houston, TX 77027-9506

- Texas (Central): (800) 743-0959

**LOS ANGELES DIVISION OFFICE**

255 East Temple Street, 20th Floor

Los Angeles, CA 90012

- California (Central): (213) 621-6690
- Hawaii: (808) 415-9522
- Nevada: (866) 415-9823
- Trust Territory: (213) 856-2216

**MIAMI DIVISION OFFICE**

8400 N.W. 53rd Street

Miami, FL 33165

- Florida: (305) 590-4680

**NEWARK DIVISION OFFICE**

80 Mulberry Street, 2nd Floor

Newark, NJ 07102

- New Jersey: (866) 366-1071

**NEW ORLEANS DIVISION OFFICE**

3638 N. Claiborne Ave

Lakeway III, Suite 1800

Metairie, LA 70002

- Alabama: (888) 514-8514
- Arkansas: (888) 514-7301
- Louisiana: (888) 514-7302
- Mississippi: (888) 514-7302

**NEW YORK DIVISION OFFICE**

199 Tenth Avenue

New York, NY 10011

- New York: (888) 683-6798
- New York: (212) 337-1593
- New York: (212) 337-1594

---

**PHILADELPHIA DIVISION OFFICE**

William J. Green Federal Building

600 Arch Street, Room 10224

Philadelphia, PA 19106

- Delaware: (888) 593-8234
- Pennsylvania: (888) 393-8231

**PHOENIX DIVISION OFFICE**

3010 N. 2nd Street, Suite 301

Phoenix, AZ 85012

- Arizona: (800) 741-0902

**SAN DIEGO DIVISION OFFICE**

4591 Viewridge Avenue

San Diego, CA 92123-1637

- California (Southern): (800) 284-1152

**SAN FRANCISCO DIVISION OFFICE**

450 Golden Gate Avenue, 14th Floor

P.O. Box 36035

San Francisco, CA 94102

- California (Northern): (866) 304-3251

**SEATTLE DIVISION OFFICE**

400 Second Avenue, West

Seattle, WA 98119

- Alaska: (888) 219-4261
- Idaho: (888) 219-4261
- Oregon: (866) 219-4261
- Washington: (866) 219-1418

**ST. LOUIS DIVISION OFFICE**

517 South 10th Street

St. Louis, MO 63103

- Iowa: (888) 603-1179
- Kansas: (888) 603-1179
- Missouri: (888) 603-1179
- Nebraska: (888) 603-1179
- South Dakota: (888) 603-1179

**WASHINGTON, D.C. DIVISION OFFICE**

Techworld Plaza

300 K Street, N.W., Suite 500

Washington, D.C. 20001

- District of Columbia: (877) 801-7947
- Maryland: (877) 330-4870
- Virginia: (877) 801-7947
- West Virginia: (877) 330-6670

---

2006 Edition

Page 63